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Getting largemacromolecules through theplasmamembraneandendosomalbarriers remainsamajorchallenge.
Here, we report a generalizable method of delivering proteins and ribonucleoproteins (RNPs) to cells in vitro and
mouse liver tissue in vivo with engineered ectosomes. These ectosomes, referred to as ‘‘Gectosomes,’’ are de-
signed to co-encapsulate vesicular stomatitis virus G protein (VSV-G) with bioactive macromolecules via split
GFP complementation. We found that this method enables active cargo loading, improves the specific activity
ofcargodelivery, and facilitatesGectosomepurification.Experimentalandmathematicalmodelinganalysessug-
gest that active cargo loading reduces non-specific encapsulation of cellular proteins, particularly nucleic-acid-
binding proteins. Using Gectosomes that encapsulate Cre, Ago2, and SaCas9, we demonstrate their ability to
execute designed modifications of endogenous genes in cell lines in vitro and mouse liver tissue in vivo, paving
the way toward applications of this technology for the treatment of a wide range of human diseases.
INTRODUCTION
The capability to delivermacromolecules such asproteins and nu-
cleic acids into mammalian cells is of considerable interest to re-
searchers and pharmaceutical industries. Innovative methods for
gene modification and interfering with mRNA expression have
become nearly indispensable tools for biomedical research
(Doudna and Charpentier, 2014; Shalem et al., 2015). All these
methods rely on the delivery of nucleic acids, proteins, or ribonu-
cleoprotein (RNP) to the intracellular space of target cells, which is
limited because the plasma and the endosome membrane are
mostly impermeable to biologics. Finding ways to circumvent
these barriers to deliver biomolecules in a pharmacologically
consistent manner remains a significant challenge (Cocucci and
Meldolesi, 2015; Fu et al., 2014; Maeder and Gersbach, 2016).
Extracellular vesicles (EVs) are heterogeneous, nano-sized
membrane vesicles that are either constitutively or inducibly
released by all cell types (Mathieu et al., 2019; Raposo and
Stoorvogel, 2013; van Niel et al., 2018). Since EVs are increas-
ingly being recognized as a native means of transporting bioac-
tive molecules between cells, there is a growing interest in
exploring EVs as delivery vehicles for therapeutics. However,
several critical issues need to be addressed to realize EVs’ trans-
lational potentials. First, various EVs, including exosomes, ecto-
somes/microvesicles, apoptotic bodies, and exomeres, are pre-
sent in conditioned media or bodily fluids (Jeppesen et al., 2019;
Mathieu et al., 2019). Methods to separate and purify each entity
in sufficient quantities remain elusive (Tkach and Théry, 2016).
Second, the specific activity of EVs tends to be low due to the
heterogeneity of their cargos. In certain applications, loading
exosomes with siRNA in vitro significantly improves the specific
activity and efficacy of encapsulated therapeutic nucleic acid
(Kamerkar et al., 2017). However, it is unclear whether this strat-
egy can be extended to larger biomolecules such as proteins or
RNP. Finally, proteomics and RNA-seq analyses reveal a great
deal of diversity and heterogeneity of EV composition (Haraszti
et al., 2016; Jeppesen et al., 2019; Kowal et al., 2016; Mangeot
et al., 2004; Mathieu et al., 2019). Challenges remain to gain con-
trol of the molecular cargo encapsulated by each type of vesicle
and to reduce the heterogeneity of EV composition.
Here, we report a general method for making programmable,
highly fusogenic vesicles, which we call ‘‘Gectosomes’’ (VSV-G
protein ectosomes), as vehicles for the dose-controlled delivery
of bioactive macromolecules in vitro and in vivo. Borrowing from
mechanisms of vesicular stomatitis viral delivery and proficient fu-
sogenic activity of vesicular stomatitis virus G protein (VSV-G), we
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Figure 1. Development of a Two-Component Fluorescent Gectosome for Intercellular Transfer of Specific Proteins
(A) The size distribution of VSV-G-sfGFP particles by flow cytometry using FACSAria Fusion Cell Sorter. Size reference beads were used as the standard. Dot
plots are representative of three individual experiments.
(legend continued on next page)
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developed an active cargo-loading strategy for Gectosomes us-
ing the split GFP system (Cabantous et al., 2005). Modeling and
experimental studies show that active loading of Gectosomes
via GFP complementation greatly increases the efficiency of
cargo delivery to target cells and reduces non-specific encapsu-
lation of cellular proteins. We demonstrated the versatility and
broad applicability of this approach by the successful intracellular
delivery of cytosolic and nuclear enzymes, resulting in the execu-
tion of DNA recombination, RNA interference, and gene editing in
cultured cells andmice liver tissues in vivo. SinceGectosomes are
genetically encoded, highly programmable, easy to prepare, and
amenable to purification based on their cargo, this approach sim-
plifies genome modification experiments and can be adapted to
wide-ranging research and possible therapeutic applications.
Design
Delivering proteins and nucleic acids into the cytosol and nucleus
is limited by the plasma and the endosome membrane barriers.
EVs are capable of overcoming these barriers of entry to mediate
intercellular transfer of the encapsulated macromolecular cargos.
However, themajor challenges for delivering intracellular biologics
with EVs are the lack of control of the cargo content and the
inability to isolate EVs loaded with defined cargo. We have devel-
oped an engineering method for making a specific type of EVs
called Gectosomes, which facilitate cargo loading and their endo-
somal escape simultaneously. Gectosomes contain two major
components: an engineered VSV-G and the cargo of interest teth-
ered to one another via split GFP. Complementation of split GFP
enables more efficient loading of the specific cargo and purifica-
tion of desired fluorescent Gectosomes. We validated the func-
tionality of engineered Gectosomes for delivering proteins or pro-
tein/RNA complexes designed to modify genotypes in
mammalian cells in vitro and live animals in vivo.
RESULTS
Overexpression of VSV-G in Human Cells Elevates the
Production of VSV-G-Containing EVs
Enveloped viruses often make use of their virus-encoded fusion
protein to facilitate membrane fusion with host cells during
infection (Albertini et al., 2012). VSV-G is one of the best-stud-
ied viral fusion proteins and is frequently used for pseudotyping
retroviral or lentiviral particles to enable their entry into a broad
range of cell types (Hirschberg et al., 1998; Lodish and Weiss,
1979). During our investigation of the pseudotyping activity of
superfolder GFP tagged VSV-G (VSV-G-sfGFP), we noticed
that copious amounts of small fluorescence particles ranging
in size between 100 and 1,000 nm were present in the culture
media from cells transfected solely with VSV-G-sfGFP by flow
cytometry analysis (Figure 1A). To characterize these particles,
we transiently transfected 293T cells with sfGFP or VSV-G-
sfGFP expression vectors (Figure S1A) and harvested superna-
tants for NanoSight tracking analysis (NTA) (Figures 1B and
S1B). We found that supernatant from VSV-G-sfGFP-trans-
fected cells contained ~2 3 109 particles per mL with an
average size of ~200 nm in the GFP fluorescence channel. In
contrast, only ~1.6 3 106 particles per mL were detected in
the same channel for the control transfection with sfGFP. The
total number of EV particles per mL present in the media was
comparable based on the particle counts in the clear channel
(Figure 1B). Thus, VSV-G transfection favors the production
of fluorescent vesicles by ~1,000-fold in 293T cells.
To determine whether VSV-G is present on the fluorescent
vesicles, we incubated the VSV-G-sfGFP and the control super-
natants with magnetic beads coated with amonoclonal antibody
(8G5F11) against VSV-G (Lefrancois and Lyles, 1982). Strong
bead fluorescence was observed with VSV-G-sfGFP superna-
tant but in neither the control nor beads without antibody, sug-
gesting VSV-G is present on the surface of these particles (Fig-
ure S1C). To examine the morphology of these fluorescent
vesicles, we performed transmission electron microscopy
(TEM) and VSV-G immunogold labeling studieswith the immuno-
purified vesicles (Figure 1C). The imaged particles show the ex-
pected round-shaped vesicles with an average diameter
~128 nm, which is slightly smaller than the average size deter-
mined by NTA or flow cytometry and could be due to the effects
of sample fixation. Immunogold labeling with an anti-VSV-G anti-
body demonstrates that VSV-G is present on the surface of the
vesicle (Figure 1C). These results show that VSV-G promotes
the robust production of EVs enriched with this protein on the
surface. Hereafter, we refer to VSV-G-containing EVs as ‘‘Gecto-
somes’’ for viral G-protein-containing ectosomes.
(B) Nanoparticle tracking analysis of the size distributions and concentrations of extracellular vesicles in the supernatants from sfGFP, VSV-G-sfGFP, or VSV-G-
GFP11/BlaM-Vpr-GFP1-10-transfected cells. Data are mean ± SD for technical replicates (n = 3) and are representative of 10 individual experiments.
(C) Representative TEM and TEM immunogold images of VSV-G-sfGFP vesicles. Primary antibody: 8G5F11 VSV-G antibody; secondary antibody: goat anti-
mouse IgG/M 6 nm.
(D) Schematic illustration showing VSV-G Gectosome-mediated BlaM protein transduction and detection in the target cell. The schematic model is not drawn to
the scale.
(E and F) Flow cytometric analysis of CCF2-AM dye-loaded target HeLa cells (~3 3 105) incubated with vesicles collected from the supernatants of the same
number of producer 293T cells (~106) transfected with the same amount of plasmids as shown. Representative dot plots and the quantification of BlaM-positive
cells are reported (mean ± SD, n = 3). Data are representative of two individual experiments.
(G) Schematic diagram of the Cre transduction experiment (not to scale).
(H and I) Flow cytometric analysis of the color conversion of target cell 293ColorSwitch. 293ColorSwitch cells (~1 3 105) were treated for 48 h with extracellular
vesicles (total particle number, ~43 109; GFP-positive particle number, ~43 108) collected from supernatants of 293T cells transfected with plasmids as shown.
Data are mean ± SD (n = 3), and dot plots are representative of three individual experiments.
(J) Color conversion of target 293ColorSwitch cell (~13 105) with VSV-G/Cre Gectosomes (~83 108) or VSV-G-NJ/Cre Gectosomes (~83 108) in the presence of
VSV-G antibody (8G5F11, 1:100) or control IgG; VSV-G-NJ is the G protein from vesicular stomatitis virus New Jersey strain. Data are mean ± SD (n = 3).
(K) Performance of Gectosomes versus artificial liposomes in Cre delivery to 293ColorSwitch cells. The plot shows the percentage of cells switched upon
exposure to the indicated liposomes or Gectosomes containing the indicated amount of Cre as determined by flow cytometry analysis. Data are mean ± SD (n =
3). Statistical significance for (F), (I), and (J) was assessed using Student’s t test, ***p < 0.001; n.s., not significant.
See also Figures S1 and S2.
ll
Technology
Developmental Cell 55, 1–18, December 21, 2020 3
Please cite this article in press as: Zhang et al., Programmable Extracellular Vesicles for Macromolecule Delivery and Genome Modifications, Devel-
opmental Cell (2020), https://doi.org/10.1016/j.devcel.2020.11.007
Development of Two-Component Fluorescent
Gectosomes for Intercellular Transfer of Specific
Proteins
Previous work showed that highly concentrated VSV-G EVs
could mediate intercellular transfer of VSV-G and a variety of
cellular proteins with low selectivity (Mangeot et al., 2011). Pas-
sive loading of VSV-G and cargos into vesicles makes these type
of EVs highly heterogeneous and low efficiency for delivering
specific cargo proteins. We aimed to develop an active loading
strategy to recruit specific proteins into Gectosomes and
enhance the specificity of cargo delivery. To this end, we used
a split GFP system as the building block to construct a two-
component Gectosome (Figure S1D, middle panel). Waldo and
colleagues discovered that GFP could be split between the tenth
and eleventh b-strands, resulting in separate constructs of a 16-
amino acid (aa) fragment (GFP11) and the rest of the protein
(GFP1-10) (Cabantous et al., 2005). Without the 16-aa peptide,
GFP1-10 is nearly non-fluorescent. Upon co-expression of
both fragments in cells, GFP11 binds GFP1-10 to reconstitute
a functional, fluorescent GFP molecule. To determine whether
the split GFP systemcould be used to bridge VSV-G and its bind-
ing partners in cells, we fused VSV-G with GFP11 at its C termi-
nus (VSV-G-GFP11) and a b-lactamase-vpr reporter (BlaM-Vpr)
with GFP1-10 at its C terminus (BlaM-Vpr-GFP1-10) (Figure 1D).
293T cells exhibited higher GFP fluorescence when VSV-G-
GFP11 and BlaM-Vpr-GFP1-10 were transfected together
compared with those that were transfected individually by flow
cytometry (Figure S1A, green versus black traces) or confocal
microscopy analyses (Figure S1E). These results confirm that
VSV-G can find its intended cargo protein in cells.
To deliver encapsulated cargos to target cells, two-compo-
nent Gectosomes need to be efficiently released from the pro-
ducer 293T cells (Figure 1D). Supernatant from 293T cells trans-
fectedwith the split GFP constructs was collected and subjected
to NTA. As expected, VSV-G-GFP11/BlaM-Vpr-GFP1-10 parti-
cles (VSV-G/BlaM Gectosomes) are fluorescent, and their
average size was similar to VSV-G-sfGFP particles (sfGFP Gec-
tosomes), although the yield was slightly lower (33 108 particles/
mL) (Figures 1B and S1B). To confirm the secretion and validate
the biochemical composition of two-component Gectosomes,
we performed subcellular fractionations followed by western
blotting analysis. The result verified that VSV-G and BlaM are
released from cells and present in the extracellular vesicle frac-
tions (Figure S1F). To test whether two-component Gectosomes
can transfer encapsulated cargo proteins from producer cells
(293T) to target cells (HeLa), we incubated VSV-G/BlaM Gecto-
somes with HeLa cells. BlaM-Vpr reporter was selected because
its enzyme activity can be easily measured by flow cytometry
with CCF2-AM, a cell-permeable fluorescence resonance en-
ergy transfer (FRET) substrate, which consists of a cephalo-
sporin core linking 7-hydroxycoumarin to fluorescein (Cavrois
et al., 2002). BlaM catalyzes the reaction that severs the linkage
between the two dyes leading to a loss of FRET so that exciting
the coumarin at 409 nmnowproduces a blue fluorescence signal
at 447 nm instead of the FITC signal at 488 nm. As shown in Fig-
ures 1E and 1F, only supernatant from 293T cells co-transfected
with both constructs is capable of delivering BlaM to HeLa or
293T cells (Figures S1G and S1H). Moreover, cleavage of
CCF2-AM is BlaM specific as Gectosomes produced by co-
transfection with Cre-GFP1-10 (see below) have minimal activity
(Figures S1G and S1H). As a control, we included a VSV-G
mutant (P127D) shown to be defective in membrane fusion
(Votteler et al., 2016). This mutant does not affect Gectosomes
production or release from the producer cells (Figures 1E, S1A,
S1E, and S1F). However, BlaMGectosomes with fusion deficient
VSV-G (P127D)-GFP11 fail to mediate the transfer of BlaM-Vpr-
GFP1-10 to target cells (Figures 1E and 1F). These results
suggest fusion is critical for Gectosomes cargo delivery, which
is consistent with the role of VSV-G in mediating endosome
escape of viral particles (Weissenhorn et al., 2007, 2013).
Robust and Dose-Controlled Intracellular Delivery of
Macromolecules by Gectosomes
For exogenous proteins or nucleic acids to reach their intracel-
lular targets, EVs need to fuse with the target cell either at the
plasma membrane or inside the endosome following endocy-
tosis. To further evaluate the capability of Gectosome delivery,
we tested whether proteins that act on nuclear targets can be
transferred from producer cells to target cells. Cre recombinase
was selected for these studies since the function of Cre can be
readily measured with 293ColorSwitch cells, which stably ex-
press a color switch reporter (Zomer et al., 2015). Upon Cre up-
take, cells switch from a strong RFP to a GFP signal due to the
excision of a floxed RFP-STOP cassette (Zomer et al., 2015) (Fig-
ure 1G). We fused Cre with GFP1-10 (Cre-GFP1-10) and co-ex-
pressed it with VSV-G-GFP11 in 293T cells (Figure S2A). As with
VSV-G/BlaM Gectosomes, the fluorescent Cre Gectosomes
were producedmassively (~3.83 109 particles/mL). The average
size of the Cre Gectosomes is about ~185 nm in diameter, but
the particles appear to be more homogeneous (Figure S2B) by
NTA analysis. To determine whether split GFP enables higher ef-
ficiency of Cre delivery, we incubated comparable numbers of
Gectosomes from mock, VSV-G-GFP11/Cre-GFP1-10, and
VSV-G-sfGFP/Cre-GFP1-10 with 293ColorSwitch cells for 48
h. We found that 66.9% of 293ColorSwitch cells were switched
to GFP with Cre Gectosomes, while vesicles from untethered
VSV-G-sfGFP/Cre-GFP1-10 resulted in only 2.6% switch, pre-
sumably due to passive cargo loading (Figures 1H and 1I). The
effect of Cre-mediated recombination and the time course of
this switching process were confirmed by confocal microscopy
and flow cytometry respectively (Figures S2C–S2E). The same
vesicles produced only background fluorescent signals in con-
trol 293T cells (Figure S2D). As a control, we also compared
two-component Cre Gectosomes with one-component Gecto-
somes (i.e., direct VSV-G-Cre fusion, Figures S2F and S2G).
No significant cell switch was observed with one-component
VSV-G-Cre Gectosomes. These results indicate that bioactive
Cre delivered by two-component Gectosomes efficiently enters
the nucleus to mediate Cre-lox recombination in target cells and
that active loading of Cre via split GFP greatly increases (~26-
fold) the efficiency of this process.
Cellular uptake of Gectosomes may require specific interac-
tion between VSV-G and receptor proteins present on the sur-
face of target cells. The specificity and requirements of VSV-G
for Gectosome delivery of Cre were investigated with a variant
of VSV-G from the vesicular stomatitis virus New Jersey strain
(VSV-G-NJ) and a VSV-G antibody (8G5F11) that only binds
VSV-G of the Indiana strain, which we used throughout this
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work. As shown in Figure 1J, VSV-G-NJ is also capable of effi-
ciently delivering Cre (Munis et al., 2018). Conversely, upon incu-
bationwith 8G5F11, Cre transfer by VSV-Gwas completely abol-
ished while VSV-G-NJ mediated transfer was barely affected.
These results demonstrate that Gectosome delivery requires
VSV-G interaction with the cell membrane and subsequent
fusion for efficient cargo release.
How does Gectosomal delivery compare with other dose-
controlled delivery systems? Liposomes are well-established
vehicles for the delivery of nucleic acids but are known to be
not optimal for protein delivery (Colletier et al., 2002; Yu et al.,
2019, 2015, 2018; Zelphati et al., 2001). To compare the delivery
efficiency of Gectosomes with liposomes, we first quantified the
amount of Cre encapsulated in Gectosomes using recombinant
Cre as the standard for immunoblotting (Figure S2H). Next, we
prepared liposomes encapsulating a defined amount of recom-
binant Cre using previously optimized methods (Yu et al.,
2019, 2015, 2018) (Figure S2I). Approximately 510 nM of Cre
delivered by liposomes is required to produce 19.3% of cells
to switch. With Gectosomes, a similar effect is achieved with
about 0.81 nM of Cre (Figures 1K, S2I, and S2J). Thus, based
on the Cre amount delivered, Gectosomes showed ~630-fold
higher delivery efficiencies than liposomes. These results
demonstrate that Gectosomes outperform liposomes in deliv-
ering Cre into the nucleus, presumably due to better endosome
escape or more robust fusion (Albertini et al., 2012).
Functional Separation of Gectosomes from Exosomes
Although exosomes and Gectosomes differ in size and intracel-
lular origin, both can load protein or nucleic acid cargos from
producer cells and transfer them to target cells. We wondered
whether the active cargo-loading strategy we developed for
Gectosomes could be extended to exosomes. To test this
notion, we inserted GFP11 to the C-terminal of CD9 and CD81;
two protein markers are known to be present on the surface of
exosomes (Raposo and Stoorvogel, 2013). Next, we co-ex-
pressed CD9-GFP11, CD81-GFP11, or VSV-G-GFP11 together
with Cre-GFP1-10 in 293T cells to produce exosomes and Gec-
tosomes (Figure 2A). Successful and robust reconstitution of the
GFP signal was seen with all three pairs (Figure 2B). NTA of the
conditioned media from the transfected cells confirmed that
fluorescent EVswere produced at comparable levels (Figure 2C).
While Gectosomes triggered a robust color switch (~86%)
consistent with the transfer of Cre, less than 3% of cells were
switched with CD9 EVs, and even lower efficiency of the switch
with CD81 EVs was observed (0.4%) when similar numbers of
fluorescent particles were applied (Figure 2D). Although both
the loading strategy and production of fluorescent EVs are com-
parable between types of encapsulation, intracellular delivery ef-
ficiency is vastly different. This result suggests that CD9- or
CD81-containing vesicles, presumably exosomes, are function-
ally distinct from Gectosomes for protein transduction.
Differentiating and classifying EVs remains a major challenge
due to their heterogeneity in size and contents. If Gectosomes
and exosomes are separable entities in their biogenesis, we
would expect that perturbing the biogenesis of one entity should
have minimal effect on the other. Previous studies showed that
acute Ca2+ spikes stimulate exosome release in a Munc13-4-
dependent manner and that knockdown of this protein signifi-
cantly inhibited exosome secretion (Messenger et al., 2018). To
test whether Munc13-4 differentially regulates Gectosome and
exosome production in 293T cells, we selected stable cell pools
expressingMunc13-4 sgRNA and SpCas9 by lentiviral infection.
Western blotting showed apartial loss ofMunc13-4 expression in
the selected cell pool (Figure 2E). In agreement with previous re-
sults, significant reductions in CD9, GW130, and GAPDH levels
were observed in supernatant collected from Munc13-4-edited
cells (Figure 2E), consistent with inhibition of exosome release.
To determine whether Munc13-4 perturbation also affected the
secretion of both endogenous and exogenous CD9, we tran-
siently co-transfected CD9-GFP11 and Cre-GFP1-10 into wild-
type and Munc13-4-edited cells (Figure S3A). The expression
ofCD9-GFP11/Cre-GFP1-10 inwild-typecellswas indistinguish-
able fromexpression in edited cells (Figures 2FandS3A).Howev-
er, the number of GFP-positive CD9 exosomes fromMunc13-4-
edited cells was ~2-fold lower than from wild-type cells, as
measured by FACS (Figures 2G and S3B). Thus, the depletion
of Munc13-4 causes intrinsic defects in the production of CD9-
positive exosomes. To investigate Gectosome production, we
transfected wild-type and Munc13-4-edited cells with VSV-G-
GFP11 and BlaM-Vpr-GFP1-10. We found that fluorescent Gec-
tosome secretion is comparable between these two cell lines
(Figure 2H), and the efficiency of BlaM delivery to HeLa cells is
also indistinguishable between the Gectosomes collected from
those twoproducer cell lines, indicating that Gectosome produc-
tion is independent of Munc13-4 (Figure 2I).
We further investigated whether Gectosomes can be sepa-
rated from exosomes biochemically. Using magnetic beads
coated with an anti-CD9 antibody, we depleted CD9 exosomes
from VSV-G-GFP11/Cre-GFP1-10 Gectosomes and measured
the remaining Gectosome activity following serial dilutions (Fig-
ures S3C–S3E). Only a small reduction in Gectosome activity
was observed (Figures S3C and S3D), suggesting that the bulk
of Gectosome activity is not significantly affected by the removal
of CD9 exosomes.
Finally, we also tested the effect of GW4869, a potent neutral
sphingomyelinases inhibitor known to block exosome biogen-
esis (Menck et al., 2017), on Gectosome production in the pro-
ducer cells. Following mock and co-transfection of VSV-G-
GFP11/Cre-GFP1-10, 293T cells were treated with GW4869
(10 mM) to assess the effect on CD9 production and Gectosome
activity. As expected, GW4869 reduced CD9 exosome secretion
in both mock and Gectosome-producing cells (Figure S3F),
whereas the activity of VSV-G-GFP11/Cre-GFP1-10 was not
affected (Figure S3G). This result further supports that Gecto-
somes and exosomes are functionally separable.
Purification, Quantitation, and Mathematical Modeling
of Gectosomes
Using a well-established protocol developed for purification of
exosomes (Kowal et al., 2016), we tried to separate Gectosomes
from other EVs by differential ultracentrifugation (UC) and flota-
tion in a density gradient. While this procedure effectively en-
riches exosomes as measured by CD9 and GM130, Gecto-
somes components are also enriched in 100-K UC sediments
(Figure S4A). To solve this problem, we developed a scalable pu-
rification protocol for Gectosomes that involves four major steps
(Figure 3A). After two differential centrifugation steps, we applied
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Figure 2. Functional Separations of Gectosomes from Exosomes
(A) Schematic diagram of experimental design (not to scale).
(B) Representative histograms of flow cytometric analysis of 293T cells transiently transfected with plasmids as shown.
(C) Nanoparticle tracking analysis of EVs from culture supernatants of 293T cells transfected with the indicated plasmids. Data are mean ± SD (n = 3).
(D) Flow cytometric analysis of 293ColorSwitch cells incubated with Cre Gectosomes, BlaM Gectosomes, or CD9/CD81-labeled exosomes. Representative dot
plots and the quantification of switched cells are reported (mean ± SD, n = 3).
(E) Western blot of Munc13-4, CD9, and GW130 in wild-type and Munc13-4 knockout 293T cells.
(F) Flow cytometric analyses of the transfection efficiency of CD9-mCherry plasmid in wild-type and Munc13-4 knockout 293T cells.
(G) Nanoparticle tracking analysis of the percentage of CD9-GFP11/Cre-GFP1-10-positive exosomes secreted from wild-type and Munc13-4 knockout
293T cells.
(H) Nanoparticle tracking analyses of the concentrations of BlaM Gectosomes secreted from wild-type and Munc13-4 knockout 293T cells.
(I) Flow cytometric analysis of CCF2 cleavage in HeLa cells transduced with BlaM Gectosomes fromMunc13-4 knockout or wild-type 293T cells. Data for (F)–(I)
are mean ± SD (n = 3). Statistical significance was assessed using Student’s t test. **p < 0.001; n.s., not significant.
See also Figures S3 and S4.
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Figure 3. Purification, Quantitation, and Mathematical Modeling of Gectosomes
(A) The flowchart of the Gectosome purification procedure.
(B and C) Flow cytometric and western blotting analysis of Cre Gectosome fractions off the IZON qEVoriginal column. EVs pre-cleaned by 10,000 3 g centri-
fugation were loaded onto the IZON qEVoriginal column. The fractionations 1–8 were incubated with VSV-G antibody crosslinked magnetic beads. The beads
were washed, and a portion of the beads was subjected to flow cytometric analysis (B) and western blotting analysis (C). UC denotes samples prepared by
ultracentrifugation (100,000 3 g, 90 min).
(D) The ratios of VSV-G-GFP11/Cre-GFP1-10 in factions 2 and 3 or UC were calculated based on band intensities in (C).
(E) The percentages of VSV-G-GFP11, CD9, and GM130 in the fractions 2 and 3 versus the corresponding proteins in the UC sample were calculated based on
relative band intensity in (C).
(F) 3Dmathematical modeling of the Cre Gectosome. The left panels show an outside view of a modeled prototypical Gectosome and its local zoom-in view. The
right panel shows themiddle intersection view of a Gectosome and its local zoom-in view. This 3Dmodel is illustrated according to the space-filling of 5,620 VSV-
G-GFP11 molecules and 933 Cre-GFP1-10 molecules in a Cre Gectosome. The numbers of proteins of interest in this model are derived from the quantitative
western blotting results in Figures S4B–S4D and 3C. Data are mean ± SD (n = 3); statistical significance for (D) was assessed using Student’s t test (**p < 0.01;
***p < 0.001). UC, ultracentrifugation.
See also Figure S4.
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Figure 4. Active Loading of Gectosomes via the Split GFP System Reduces the Passive Incorporation of Cellular Proteins
(A) Illustration of the experimental design showing the competitive encapsulation of cargo protein of interest into Gectosomes. Cre-GFP1-10 is the cargo protein
of interest, and untagged BlaM is used as a proxy for measuring non-specific incorporation of proteins into Gectosomes.
(B) The expression of VSV-G-GFP11, Cre-GFP1-10, and BlaM proteins in 293T cells lysates (left panel, ~105 cells/lane) transfected with plasmids shown, and
ultracentrifugation concentrated supernatants (right panel, ~8 3 109 particles/lane). Balance refers to non-specific DNA that was included to ensure the same
amount of total input DNA.
(legend continued on next page)
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the resuspended 10K pellet on a qEV 70 nm (IZON) size SEC col-
umn and collected the fractions with FITC fluorescence. Mag-
netic beads with immobilized anti-VSV-G 8G5F11 antibody
were used to capture the Gectosomes before final elution with
low pH glycine. Shown in Figures 3B and 3C, most Gectosomes
are present in the second and third qEV fractionations based on
the fluorescence intensity and captured VSV-G-GFP11 and Cre-
GFP1-10 by western blot. VSV-G versus Cre ratios in fraction 2/3
are increased dramatically compared with that of the UC sample
(Figures 3C and 3D). While 100,000 3 g ultracentrifugation frac-
tionation results in highly enriched CD9 and GM130 (Figures S4A
and 3C), IZON fractionation followed by immunocapture signifi-
cantly decreases CD9 and GM130 but increases VSV-G in frac-
tions 2 and 3 when compared with the corresponding proteins in
UC samples (Figures 3C and 3E). This result suggests that our
purification protocol is very effective in removing exosomes,
while the residual amount of CD9 in the Gectosome fractions
may come from the cell surface. This result also further supports
a biochemical distinction between Gectosomes and exosomes.
To develop a 3Dmolecular model for a prototypic Gectosome,
we first performed quantitative measurements of VSV-G and Cre
in Gectosomes by immunoblotting using purified recombinant
proteins as standards (Clarke et al., 2006; Clarke and Liu,
2010). The number of VSV-G-GFP11 and Cre-GFP1-10 is esti-
mated at ~5,620 and ~933 molecules respectively per gecto-
some (Figures S4B–S4D). We constructed a 3Dmolecular model
of a Gectosome filled with VSV-G, sfGFP, and Cre from their
known molecular structures in PDB using 3D software Blender
(https://www.blender.org) (Figures S4E and 3F). The model de-
rives from the ‘‘best guess’’ numbers (Table S1 and STAR
Methods) and needs to be refined when better analytical tech-
niques become available. Nevertheless, an average gectosome
model can guide our understanding of Gectosomes. In this
model, Cre-GFP1-10 occupies about ~13% of the total lumen
space and spatially fills ~41% the hollow sphere beneath the in-
ner membrane due to its strong association with VSV-G-GFP11
(Kd<1 nM) (Cabantous et al., 2005; Köker et al., 2018) (Figure S4E
and STARMethods). Themodeling results prompted us to inves-
tigate what other proteins may be present in Gectosomes and
whether active loading of Cre-GFP1-10 deters the recruitment
of certain cellular proteins.
Active Loading of Gectosomes via the Split GFP System
Reduces Passive Incorporation of Cellular Proteins
We considered two possible models of cargo encapsulation in
Gectosomes with the split GFP system. One model is that active
loading of Cre-GFP1-10 simply adds to the repertoire of existing
proteins in Gectosomes without changing its baseline composi-
tion. A second competing model is the encapsulation of Cre-
GFP1-10 remodels Gectosomes by specifically outcompeting
other cellular proteins. The second model predicts that an
increasing amount of Cre-GFP1-10 in Gectosomes will reduce
non-specific incorporation of a cytosolic reporter protein. To
test this model, we transfected 293T cells with the same amount
of VSV-G-GFP11 while varying the ratio of input Cre-GFP1-10
(specific protein) to BlaM (non-specific protein). Gectosomes
were collected and incubated with either 293ColorSwitch or
HeLa cells tomeasure the activity of these two enzymes, respec-
tively (Figure 4A). Supernatants and cell lysates were also blotted
with relevant antibodies to verify the amount of Cre and BlaM in
Gectosomes (Figure 4B). The increasing Cre-GFP1-10 lowers
non-tethered BlaM in Gectosomes, which is corroborated by
the activity of Cre and BlaMmeasured in two cell lines described
above (Figure 4C).
To directly test the second model, we purified Gectosomes
produced by co-transfection with VSV-G-GFP11 along with
untethered BlaM with or without specific cargo protein Cre-
GFP1-10 i.e., VSV-G-GFP11/BlaM (VB) versus VSV-G-GFP11/
Cre-GFP1-10/BlaM (VCB) (Figure 4A). Since Gectosomes
encapsulate untethered BlaM protein, we reasoned that it could
serve as a proxy for non-specific recruitment. Harvested Gecto-
somes were immunocaptured with anti-VSV-G agarose beads
and subsequently eluted off the beads with 1% SDS buffer. An
equal amount of input proteins in duplicates were digested
with trypsin and analyzed by label-free quantification (LFQ)
mass spectrometry (MS). The values of Log2 LFQ intensity of
all detected proteins are ranged from around 21 to 35, which
means the data quality is suitable for further analysis (Figure S4F;
Table S2).We first compared the Log2 LFQ intensity values of the
known proteins (VSV-G and BlaM) shared in these two Gecto-
some samples (Figure 4D; Table S2). The number of VSV-G pep-
tides detected (27 versus 26) and the Log2 LFQ intensity value
(35.58 versus 35.95) are comparable, suggesting the equivalent
amounts of VSV-G-GFP11 in two Gectosomes. Three peptides
of BlaM (Log2 LFQ intensity is 12.6) were detected in VB Gecto-
somes, in contrast, nonewas detected in VCBGectosomes. This
result suggests that BlaM is excluded in the presence of Cre-
GFP1-10, which supports the results of the experiment shown
in Figures 4B and 4C.
Next, we quantified the endogenous proteins identified in both
Gectosome samples (Table S2). MS peptide, intensity, and LFQ
data show that VCB Gectosomes carry less randomly packaged
(C) Flow cytometric analysis of 293ColorSwitch cells and CCF2-loaded HeLa (BlaM-positive) cells that were transfected using plasmids as indicated. Since
untethered BlaM in Gectosomes is very low, the supernatant was concentrated 8-fold by ultracentrifugation before incubation with HeLa cells. Data are mean ±
SD (n = 3) and are representative of three individual experiments.
(D) MS analysis of immunoaffinity-purified VSV-G-GFP11/BlaM and VSV-G-GFP11/Cre-GFP1-10/BlaM Gectosomes. The graph shows the Log2LFQ intensity of
VSV-G, BlaM, and Cre in these two types of vesicles.
(E) Label-free quantitative MS analysis of the abundances of identified proteins relative to VSV-G in the indicated Gectosomes. The abundance value of each
cargo protein is shown in Table S2. For data visualization, the abundance of VSV-G-GFP11 was assigned as 100, and the relative abundances of the rest of the
proteins identified were calculated according to their Log2LFQ intensity values relative to VSV-G-GFP11. Protein abundances in relative values to VSV-G as
determined by MS of VSV-G/Cre-GFP1-10/BlaM Gectosomes (x axis) compared with VSV-G/BlaM Gectosomes (y axis). Red lines represent the gate of 4-fold
change (FC).
(F) Pie charts showing the volume distribution of proteins in each GO category in the indicated Gectosomes by a combination of experimental and modeling
analysis.
See also Figure S4.
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endogenous proteins (Figure S4G). We plotted the Log2 LFQ in-
tensity values of all detected proteins in both samples (Fig-
ure S4H). There are about 323 proteins shared between the
two samples (Figure S4H). Of these, 27 proteins appear to be
more abundant in the VB sample. Additionally, 453 proteins
were found only in the VB Gectosomes and 41 proteins were
found only in the VCB Gectosomes. Overall, VB Gectosomes
contain more diverse set of proteins than VCB Gectosomes
do, even though both species contain an almost identical
amount of VSV-G-GFP11.
The MS data were further analyzed in the context of our 3D
molecular model. First, we ranked proteins identified in two Gec-
tosomes by their abundance relative to VSV-G-GFP11 based on
the LFQ intensity. The result showed a dramatic reduction of his-
tones in the presence of Cre-GFP1-10 (Figure 4E). Second, we
estimated the molecular volume (partial specific volume) of the
lumen proteins from their molecular weight using a simplified
biophysical equation (Erickson, 2009). This approximation al-
lowed us to compute the packing of Gectosomes in response
to active loading. We summed up the total volume of lumen pro-
teins in each Gectosome scaled to their relative abundance to
VSV-G-GFP11. The total calculated volume of these proteins ac-
counts for ~20% of our 3D molecular model’s theoretical lumen
volume for VB and VCBGectosomes (Table S3). Plotting the pro-
teins’ volume distribution according to their GO classifications
shows that major differences between VCB and VB Gecto-
some’s cargo composition are the nucleosomal and ribosomal
proteins (Figure 4F), which agrees with the abundance changes
described above (Figure 4E). Taken together, these results sup-
port a model that active Gectosome loading via split GFP out-
competes non-specific encapsulation of cellular proteins and
thereby reduces the heterogeneity of Gectosomes.
Gectosomes Can Deliver Versatile Cargos into Target
Cells and Program Gene Expression
Can Gectosomes be engineered to deliver gene modifying func-
tionality to target cells? To address this question, we designed
Gectosomes that encapsulate AGO2 (Hammond et al., 2001)
and SaCas9 (Ran et al., 2015). Flow cytometry, confocal micro-
scopy, and western blot analyses confirmed that these proteins
formed complexes with VSV-G-GFP11, mediated by split GFP,
andwere released from cells (Figures S5A–S5C). To test whether
Gectosomes can package and deliver RNA-interfering function-
ality to target cells, we used a co-transfection systemwhere cells
received Gectosomes containing GFP1-10 fused to AGO2 and
the shRNA targeting the mitochondrial kinase PINK1. AGO2 is
a component of the RNA-induced silencing complex that binds
and unwinds the small interference RNA duplex (Hammond
et al., 2001). The resulting vector, AGO2-GFP1-10, was co-
transfected with VSV-G-GFP11 into 293T cells. Another RNA-
binding protein, ELAV/HuR, was used as a negative control in
this experiment. Resulting Gectosomes were then collected for
testing. PTEN induced kinase 1 (PINK1) is a kinase that recruits
the E3 ubiquitin ligase Parkin to mitochondria in response to
the oxidative phosphorylation uncoupler, CCCP (Narendra
et al., 2010; Zhang et al., 2014), resulting in acute mitophagy.
As expected, in HeLa-Venus-Parkin-RFP-Smac cells without
Gectosomes, Venus-tagged Parkin localized diffusely in the
cytosol of unstimulated cells and relocated to mitochondria
upon CCCP treatment (Figure 5A). However, cells exposed to
Gectosomes carrying PINK1 shRNA showed reduced Parkin
accumulation on the mitochondrial surface in response to
CCCP. This blockage of Parkin recruitment was observed only
with AGO2/shPINK1 Gectosomes and not the ELAV1/shPINK1
Gectosomes; knockdown of PINK1 by AGO2/shPINK1 Gecto-
somes was confirmed with real-time PCR analysis and immuno-
blotting (Figures 5C and 5D). The imperfect correlation between
PINK1 knockdown and Parkin localization could result from the
off-target effect associated with each shRNA delivery method
(Figures 5B and 5C). Nevertheless, these results demonstrate
that Gectosomes can be programed with RNA-interfering com-
plexes to inactivate genes of interest selectively.
To investigate whether these Gectosomes can deliver a
competent gene-editing complex capable of making targeted
changes to target cells’ genomes, we collected Gectosomes
from 293T cells made by co-transfecting VSV-G-GFP11 and Sa-
Cas9-GFP1-10, with or without PINK1 sgRNA. These Gecto-
someswere incubated with HeLa cells expressing Venus-Parkin.
Without PINK1 sgRNA, SaCas9 Gectosomes did not affect
Venus-Parkin mitochondrial recruitment. In contrast, cells
exposed to SaCas9/PINK1 sgRNA Gectosomes showed a
40% reduction in the number of cells positive for Parkin recruit-
ment (Figures 5E and 5F). This was accompanied by a partial
reduction of PINK1 expression as determined by western blot-
ting (Figure 5G). The incomplete effect on PINK1 loss is likely
due to the fact that not all gene-editing events cause loss of func-
tion in a heterogeneous cell population. In addition to HeLa-
Venus-Parkin-RFP-Smac cells, we also incubated SaCas9/
PINK1 sgRNA Gectosomes with HeLa cells stably expressing
PINK1-EGFP and observed partial loss of GFP signal by flow cy-
tometry and western blot (Figures S5C–S5E). Sequencing anal-
ysis of genomic DNA from edited cells showed variable size de-
letions near the sgRNA targeting site (data not shown). These
results indicate that Gectosomes can be designed to encapsu-
late RNA interference or gene-editing machinery to alter gene
expression.
CD47 Suppresses Gectosome Clearance by
Macrophages
Circulating monocytes, macrophages, dendritic cells, and neu-
trophils remove dead cells, cell debris, exosomes, and ecto-
somes through phagocytosis (Barclay and Van den Berg,
2014). These phagocytic cells express signal regulatory protein
a (SIRPa), which serves as a receptor for CD47, a transmem-
brane protein present in high levels in tumor cells and normal
cells alike. Binding of CD47 to SIRPa triggers a ‘‘do not eat
me’’ signal (Chao et al., 2012). Previous studies showed that
the presence of CD47 on exosomes suppresses their depletion
by phagocytosis, resulting in higher exosome levels in the blood
(Kamerkar et al., 2017). In contrast, CD47 blockade with a nano-
body (nb) A4 enhancedmacrophage phagocytosis of tumor cells
(Sockolosky et al., 2016). To test if the CD47-SIRPa systemplays
a role in Gectosome clearance bymacrophages in vitro, we over-
expressed Myc and GFP11-tagged mouse CD47 or CD47nb in
293T cells, along with the standard Gectosome components
(Figure 6A). With this design, Gectosomes were generated with
higher CD47 or CD47nb expression on their surfaces, along
with VSV-G (Figure 6B). Without VSV-G-GFP11, CD47-Myc-
ll
Technology
10 Developmental Cell 55, 1–18, December 21, 2020
Please cite this article in press as: Zhang et al., Programmable Extracellular Vesicles for Macromolecule Delivery and Genome Modifications, Devel-
opmental Cell (2020), https://doi.org/10.1016/j.devcel.2020.11.007
GFP11 or CD47nb-Myc-GFP11 cannot transduce BlaM-Vpr-
GFP1-10 to target cells (Figures 6C and S6A). Next, we incu-
bated control, CD47, and CD47nb Gectosomes containing
BlaM-Vpr-GFP1-10 with mouse RAW 264.7 macrophages for 3
or 6 h. The supernatants were recovered after incubation, and
BlaM activity assays measured the amount of Gectosomes re-
maining in the media. RAW 264.7 cells depleted approximately
25% and 70% of the control Gectosomes after 3 and 6 h (Fig-
ure 6D). In contrast, only 10% and 50% of CD47 Gectosomes
were depleted, whereas 70% and 80% of CD47nb Gectosomes
were removed from the media. Gectosome depletion was also






Figure 5. Gectosomes Can Deliver Versatile Cargos into Target Cells and Program Gene Expression
(A) Confocal images of HeLa-Venus-Parkin-RFP-Smac cells transduced with Gectosomes carrying the indicated cargo proteins or nucleic acids.
(B) Quantification of the percentage of cells with Parkin on mitochondria after 10-mM CCCP treatment for 2 h in (A). n >200 cells for each condition from 3
replicates. Data are mean ± SD (n = 3).
(C) The RT-qPCR analysis of the efficiency of PINK1 knockdown in cells treated as indicated. The expression levels of PINK1 were normalized to that of GAPDH.
Results are shown as the averages ± standard error of the mean from two independent replicates (n = 2).
(D) Western blotting analysis of PINK1 protein in HeLa-Venus-Parkin cells treated as indicated.
(E) Confocal images of HeLa-Venus-Parkin-RFP-Smac cells transduced with SaCas9/sgPINK1 Gectosomes or SaCas9/sgCtrl Gectosomes.
(F) Quantitation of the percentage of cells showing Venus-Parkin accumulation on mitochondria with 10-mM CCCP for 2 h n >200 cells for each condition from
three replicates. Data are mean ± SD (n = 3).
(G) Western blotting analysis of PINK1 protein in HeLa-Venus-Parkin-RFP-Smac cells treated as shown. The relative amount of PINK1 in (D) and (G) was
quantified by densitometry. Statistical significance for (B), (C), and (F) was assessed using the Student’s t test.
See also Figure S5.
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Figure 6. CD47 Suppresses Gectosome Clearance by Macrophages
(A) Schematic illustration of the experimental procedure for evaluating the effect of CD47 on Gectosome clearance.
(B) Western blotting analysis of cargo proteins in 293T cells and released Gectosomes.
(C) Effect of CD47 or CD47nanobody expression on the efficiency of Gectosome delivery of BlaM to HeLa cells. CCF2-loaded HeLa cells were incubated with
VSV-G-GFP11/BlaM-GFP1-10 Gectosomes (with/without CD47-Myc-GFP11 or C47nb-Myc-GFP11 expression) and analyzed by flow cytometry. Data are
mean ± SD (n = 3) and are representative of two individual experiments.
(D) Measuring Gectosome depletion by RAW 264.7 cells. BlaM Gectosomes (with/without CD47 or C47nanobody co-expression) (2 mL, ~2 3 108/mL) were
incubated with RAW 264.7 macrophage cells (~106 cells/well in 6-well plate) for indicated time (0, 3, 6 h). After incubation, supernatants were retrieved by
centrifugation at 1,000 rpm for 10min to remove RAW264.7 cells. Subsequently, the retrieved supernatants (2mL) were incubatedwith HeLa cells (~33 105 cells/
well in 6-well plate) for 16 h, and then cells were loaded with CCF2-AM before they were harvested for flow cytometric analyses. The percentage of BlaM-positive
cells was normalized to 0-h incubation. Data are mean ± SD (n = 3) and are representative of two individual experiments. Statistical significance was assessed
using the Student’s t test (**p < 0.01; ***p < 0.001).
(E) Western blotting analysis of the proteins in Gectosomes collected from supernatants of 293T cells transfected with VSV-G-sfGFP with/without CD47-
Myc-GFP11.
(F) The levels of VSV-G-sfGFP Gectosomes in the mouse blood circulation 3 h after intravenous injection. Approximately 109 VSV-G-sfGFP Gectosomes
resuspended in 150 mL PBS were injected per mouse. Fluorescent Gectosomes in plasma were collected by aldehyde sulfate beads as described in
(legend continued on next page)
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left in the supernatants after macrophage exposure (Figure S6B).
The effect of CD47 on Gectosome depletion by macrophage is
not reporter specific, as Cre Gectosomes exhibit similar deple-
tion trends (data not shown).
To test if CD47 suppresses Gectosome clearance in circula-
tion in vivo, 4–6-week female BALB/cmice were injected intrave-
nously with VSV-G-sfGFP Gectosomes, produced with or
without CD47 (Figure 6E). The levels of fluorescent Gectosome
particles in circulation 3 h post-injection were measured by
flow cytometry analysis of aldehyde sulfate beads bound to
the Gectosomes in mouse plasma. VSV-G-sfGFP Gectosomes
with CD47 showed higher retention in circulation than those
without CD47 (Figures 6F and S6C). Thus, these results demon-
strate that the presence of CD47 on Gectosomes slows their
removal by myeloid cells, and conversely, that perturbing
CD47-SIRPa interactions accelerates their depletion.
PCSK9 Gene Editing in Mouse Livers through Systemic
Gectosome Delivery of Gene-Editing Machinery
Previous studies have shown that AAV viral delivery of SaCas9
and a sgRNA targeting proprotein convertase subtilisin/kexin
type 9 (PCSK9) to mouse liver cells results in a significant reduc-
tion of serum PCSK9 and total cholesterol levels (Ran et al.,
2015). Given concerns about the sustained expression of Sa-
Cas9/sgRNA expression in vivo, we wished to determine
whether Gectosomes could induce gene editing in somatic tis-
sues of animals through transient delivery of gene-editing ma-
chinery. To this end, we first confirmed the editing activity of
the two validated sgRNAs targeting PCSK9 used in the previous
studies (Ran et al., 2015) in MEF cells using Gectosome delivery
(data not shown).
To test whether Gectosome could deliver SaCas9/mPCSK9
sgRNA in vivo, we injected Gectosomes (109 per mouse per in-
jection) carrying SaCas9/mPCSK9 sgRNA to BALB/c mice on
days 0, 2, and 4. The control group was injected with PBS.
Serum PCSK9 and LDL cholesterol levels were measured in
blood samples collected on the indicated days (Figures S7A
and S7C). As early as 14 days after the initial injection, serum
PCSK9 levels were significantly lower than those of the control
groups (Figure S7A). This observation was corroborated by
immunoblotting for PCSK9 in mouse liver tissues (Figure S7B).
The serum LDL cholesterol levels also correlated with the decline
of serum PCSK9 (Figure S7C). This result suggests that gectoso-
mal delivery of the SaCas9 gene-editing complex is effective in
lowering PCSK9 expression in mouse livers.
Next, we set out to test whether CD47 can promote Gecto-
some delivery efficiency in vivo by adding two additional groups:
SaCas9 with Rosa26 sgRNA Gectosomes and CD47/SaCas9/
mPCSK9 sgRNA Gectosomes (Figure 7A). The first one serves
as the non-targeting control as Rosa26 sgRNA has been used
in previous studies (Ran et al., 2015). The CD47 group was
included based on our in vitro results showing reduced Gecto-
somes clearance by CD47. Similar to what we observed in the
initial study, animals treated with SaCas9/mPCSK9 sgRNA
Gectosomes showed a statistically significant reduction in
both PCSK9 and LDL from the control with Rosa26 sgRNA
(two-way ANOVA test) (Figures 7B–7D). The decline of LDL
cholesterol levels in all groups between day 14 and day 21
may be caused by procedure-induced stress. The CD47 group
showed consistently lower PCSK9 and LDL cholesterol levels
and higher statistical significance from the control group,
although the difference between this group and that without
CD47 was found to be not statistically significant. The dynamics
of LDL cholesterol change were unknown, but their separation
from the control groups was consistent. There were no signifi-
cant differences in body weight changes during the experiment
between the group of animals (Figure 7E), suggesting no general
systemic toxicity associated with Gectosome injection. To
further confirm the PCSK9 mutations caused by SaCas9/
mPCSK9-sgRNA Gectosomes, genomic DNA was extracted
from liver tissue, followed by PCR and DNA sequencing ana-
lyses. The results show that both deletions and mutations can
be detected in the Gectosome-treated group (Table S4), con-
firming that gene editing indeed occurred in vivo upon Gecto-
some delivery of SaCas9/PCSK9 sgRNA complex. Overall, these
results support the potential of Gectosomes to deliver effective
genome-editing machinery to animal tissues.
DISCUSSION
Here, we have developed a method for pharmacologically deliv-
ering bioactive proteins, RNA-interfering machinery, and Cas9/
sgRNA complexes in vitro and in vivo. Our method harnesses
the unique properties of fusogenic Gectosomes and an active
cargo-loading strategy to achieve the highly efficient delivery
of macromolecules to the interior of mammalian cells. We found
that active loading of Gectosomes via the split GFP system re-
duces vesicle heterogeneity by suppressing passive incorpora-
tion of cellular proteins, increases the specific activity of delivery,
and enables purification of vesicles for cargo, therebyminimizing
the undesirable effects bioactive contaminants.
Biologics designed for modulating intracellular targets are
challenging to develop as therapeutics due to their reduced abil-
ity to penetrate the cell and endosomal membranes. With the
development of genome-editing technologies and therapeutic
nucleic acids, intense efforts are devoted to addressing these
delivery issues. One of the most efficient approaches is the viral
delivery of genetically encoded biologics. However, there are
safety concerns about persistent exposure of the encoded agent
in addition to immunogenic responses, or even oncogenic trans-
formation (Nelson and Gersbach, 2016). As an alternative, lipo-
somal agents have been developed and widely used for deliv-
ering nucleic acids from DNA to RNAi. While some liposomal
gene therapies have advanced into clinical trials (Nelson and
Gersbach, 2016), liposomal delivery of protein is generally less
efficient and protein-specific due to the lack of dominant electro-
static property when compared with nucleic acids (Zuris et al.,
2015). We compared these two methods and showed that lipo-
somes require significantly more Cre protein (630-fold) to
achieve the same biological effect (Figures 1K and S2H–S2J).
STARMethods. These results are expressed as mean ± SD (n = 9) from three independent measurements for each mouse (n = 3 mice). Statistical significance for
(C) and (F) was assessed using the Student’s t test; n.s., not significant.
See also Figure S6.
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Several reasons may contribute to the high delivery efficiency of
Cre by Gectosomes. First, VSV-G mediates efficient cellular en-
try of VSV particles by endocytosis via binding to the LDL-R fam-
ily of receptors (Finkelshtein et al., 2013). Second, as a proficient
fusion protein, VSV-G promotes the fusion of viral envelope with
the early endosome membrane leading to the release of nucleo-
capsid into the cytoplasm (Albertini et al., 2012). It is highly prob-
able that VSV-G performs a similar function in Gectosome up-
take and cargo release. Third, due to the presence of
chaperone proteins such as Hsp90 and Hsp70 in Gectosomes
(Table S2) (Mangeot et al., 2011), Cre is less likely subjected to
denaturation during encapsulation as reported with liposomes
in vitro (Colletier et al., 2002). Therefore, VSV-G enables cargos
encapsulated within Gectosomes to overcome the barriers of
both the plasma and endosome membranes.
While the mechanism of VSV trafficking and nucleocapsid





Figure 7. PCSK9 Gene Editing in Mouse
Livers through Systemic Gectosome Deliv-
ery of Gene-Editing Machinery
(A) Schematic diagramof in vivomouse experiment.
(B) Time course of serum PCSK9 levels in VSV-G/
SaCas9/sgRosa26 group (n = 3 mice), VSV-G/Sa-
Cas9/sgPCSK9 group (n = 3 mice), and VSV-G/
SaCas9/sgPCSK9/CD47 group (n = 4 mice). Each
mouse received approximately 109 particles by tail
vein injection four times at 48-h interval.
(C) Western blotting analysis of PCSK9 in liver tis-
sue of mice harvested from the control and treated
groups. For the SaCas9/sgPCSK9/CD47 group,
three out of four mice were randomly selected.
Quantitation of PCKS9 levels normalized to the
loading control (b-actin) is shown below the blot.
(D) Time course of serum LDL cholesterol concen-
trations in mice injected with Gectosomes as in (B).
(E) The body weights of mice were not significantly
different between the treatment groups. Arrows
show the times of tail vein injection. Data are
mean ± SEM; statistical significance for (C) was
assessed using the Student’s t test (*p < 0.05). Two-
way ANOVA was used to determine the differences
of all titers between groups in (B), (D), and (E) (*p <
0.05; **p < 0.01; ***p < 0.001).
See also Figure S7.
whether Gectosomes follow the same
pathways to release the cargo remains un-
clear.We performed immunofluorescence
microscopy of the time course of VSV-G-
GFP11/Cre-GFP1-10 uptake in HeLa
cells. The signals for VSV-G-GFP11 and
Cre-GFP1-10 increase with the time of
exposure (Figure S7G). VSV-G-GFP11 lo-
calizes primarily on vesicular structures
and largely co-localizes with the reconsti-
tuted split GFP signal in vesicles and
membrane but not in the nucleus. In
contrast, the Cre-GFP1-10 signal is more
diffused in the cytosol, membrane, nu-
cleus, and vesicles (Figure S7G). Co-stain-
ing of VSV-G with Cre also shows that a significant fraction of the
Cre signals, especially nuclear Cre, do not co-localize with VSV-G
(Figure S7H). Cre-GFP1-10 shows a different time-dependent
accumulation pattern fromVSV-G-GFP11 intracellularly, suggest-
ing Cre-GFP1-10 splits from VSV-G-GFP11 in the recipient cells.
Gectosomes co-localize significantly with the early endosome
marker EEA1 (Figure S7I), and a small fraction of Gectosome sig-
nals co-localize with the late endosome marker Lamp1 (Figures
S7I and S7J). These results support a model that Gectosomes
enter target cells via the endocytic route, and cargo can be
released in the target cells. Two pathways for VSV cell entry
have been proposed (Albertini et al., 2012). The prevailing
pathway is that VSV-G mediates rapid fusion in early endosomes
to release cargo to the cytosol. Another pathway involves VSV
fusion with an internal vesicle inside multivesicular bodies
(MVB). In the late endosome, the nucleocapsid is released to
the cytosol through a back-fusion mechanism using the cellular
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fusion machinery (Le Blanc et al., 2005). Our data suggest that
bothpathwaysare possible forGectosomesdelivery, and the sec-
ond pathway is particularly intriguing in light of the pH-sensitive
nature of split GFP complementation (Cabantous et al., 2005).
Future studies are necessary to address the detailed mechanism
of Gectosome trafficking and cargo release.
Other groups have reported transduction of proteins or Cas9/
sgRNA complex with VSV-G ectosomes (Campbell et al., 2019;
Mangeot et al., 2011; Montagna et al., 2018). The key difference
between our study and others is the strategy of cargo loading.
Our approach enables direct tethering of cargo to VSV-G, while
others use an artificial membrane protein known as CherryPicker
to recruit cargo. We showed that the efficiency of cargo transfer
with the tethered Cre-GFP1-10 to VSV-G-GFP11 is much higher
than with the untethered one (~26-fold, Figures 1H and 1I). The
direct fusion of cargo proteins to VSV-G frequently results in
low efficiency of cargo delivery since VSV-G with fused cargo
may interfere with proper trimer formation required for fusion
(Dalton and Rose, 2001; Hung and Leonard, 2016). Rose and
colleagues showed that in functional Vesicular stomatitis virus
particles that encapsulate VSV-G-GFP, the ratio of wild-type
VSV-G to VSV-G-GFP is 4.2:1(Dalton and Rose, 2001). Our
mass spec data show the ratio of VSV-G-GFP11 to Cre-GFP1-
10 is 6:1 in Gectosomes. Since the 16-aa GFP11 tag is less likely
to perturb the fusion function of VSV-G, either the trimeric VSV-
G-GFP11 or a heterocomplex consisting of 2 units of VSV-G-
GFP11 and 1 unit of VSV-G–GFP11-cargo-GFP1-10 functions
well inmediatingGectosome fusion. Our two-component Gecto-
some design with split GFP takes advantage of this property to
enhance more specific cargo encapsulation and reduce non-
specific cellular components.
Beyond genome editing, we further demonstrated that Gecto-
somes are more versatile in delivering a variety of biologics. With
AGO2, it is possible to performRNAi with Gectosomes (Figure 5).
Although we mainly focused on delivering catalytic enzymes in
this study, it is conceivable that Gectosome-based strategies
could also be used to transduce other phenotype-modifying
agents such as therapeutic antibodies, mRNA, transcription fac-
tors, or peptides.We also envision that Gectosomes can be used
to deliver antigens and adjuvants for vaccine development.
Since proteins delivered by Gectosomes are dose-dependent,
rapidly released, and degraded intracellularly after 24–48 h, at
least in the case of BlaM (data not shown), protein or RNA trans-
duction mediated by Gectosomes is most likely transient in na-
ture and dictated by the intrinsic half-lives of the transducedmol-
ecules. This feature is particularly desirable in therapeutic
genome editing to minimize potential off-target editing that
arises from the persistent expression of Cas9 in the genome.
More experiments are needed to assess the consequences of
long-term and multi-dose exposure to Gectosomes in vivo.
One potential limitation for a broader application of Gecto-
some delivery is the adaptive immunity to VSV-G or non-human
cargo proteins. How quickly the adaptive immune system kicks
in may dictate the types of applications for which Gectosomes
can be utilized.While this may not be an issue for genome editing
or vaccine development, delivering other therapeutic modalities
may require multiple rounds of dosing over an extended period.
One potential way to address this issue is to employ different
subtypes of VSV-G (e.g., VSV-G-NJ in Figure 1J) to sidestep
the adaptive immunity through alternate dosing of different pseu-
dotyped Gectosomes. Another way of mitigating the immune
response is to decorate Gectosomes with CD47. Since CD47
slows Gectosome depletion by phagocytic cells (Figure 6), we
speculate that this strategy may reduce antigen presentation
and delay the development of adaptive immunity. Finally, there
could be endogenous VSV-G-like fusogenic proteins in human
cells. Once the host fusogenic proteins are identified, future
Gectosomes can be programed with such proteins to avoid
adaptive immunity. We aim to address these issues in our future
studies.
EVs are known to be heterogeneous. A long list of cytosolic
and nuclear proteins has been found in VSV-G ectosomes by
proteomics analysis (Mangeot et al., 2011). This heterogeneity
constitutes a major barrier to developing therapeutics due to a
lack of effective strategies to reduce heterogeneity. With an
active cargo-loading approach using split GFP, we demon-
strated that there is a significant reduction in both the number
and the abundance of cellular proteins encapsulated in Gecto-
somes by quantitative MS analysis (Figure 4). A surprising result
is that histones and nucleic-acid-binding proteins are selectively
eliminated from Gectosomes with Cre-GFP1-10. These proteins
are frequently found in exosomes and ectosomes (Haraszti et al.,
2016; Jeppesen et al., 2019; Kowal et al., 2016; Mangeot et al.,
2004). Since histones are highly basic proteins and may bind
the inner plasma membrane via electrostatic interactions, we
postulate that recruitment of Cre-GFP1-10 to the short cyto-
plasmic tail of VSV-Gmay occlude histones and other basic pro-
teins from non-specific binding to the negatively charged inner
membrane. As an additional effect, passive incorporation of nu-
cleic acids (miRNA, mRNA, and DNA) could also be reduced.
Future proteomics and NGS sequencing should help test these
hypotheses. Regardless of the mechanisms involved, our active
cargo-loading approach provides a means to reduce the hetero-
geneity of EVs and removes a considerable barrier to their devel-
opment as delivery systems.
In summary, the Gectosome approach offers a blueprint for
the intracellular delivery of biologics designed to modulate intra-
cellular targets. Future improvements in this technology may
enable the development of better therapeutics for a wide range
of human diseases.
Limitations
Because Gectosomes use a split GFP to encapsulate a specific
cargo, the functionality of the cargo of interest could be per-
turbed by the fusion with GFP1-10. It may be necessary to opti-
mize the location of GFP1-10 within the fusion partner. The sta-
bility of cargo-GFP1-10 and its affinity to VSV-G-GFP11 may
also affect the efficiency of cargo loading in producer cells and
their release in target cells. The utility of Gectosomes to deliver
intracellular therapeutics in vivo could be limited by adaptive im-
mune response development to VSV-G. We may be able to
address this issue by alternate dosing of Gectosomes pseudo-
typed with different variants of VSV-G subtypes or displaying a
sufficient amount of CD47 to mitigate antigen presentation.
Although we did not observe overt toxicity of Gectosome admin-
istration in vivo, many issues concerning safety, organ speci-
ficity, and pharmacology need to be addressed for developing
broadly applicable therapeutic solutions.
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STAR+METHODS
KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Constructs
pCMV-VSV-G-Myc Neil King/University of Washington N/A
pBbsr-VSV-G-sfGFP This paper N/A
pBbsr-VSV-G-GFP11 This paper N/A
pBbsr-VSV-G-Myc-p6Gag-GFP11 This paper N/A
pCMV-VSV-G-P127D-Myc Neil King/University of Washington N/A
pBbsr-VSV-G-P127D-Myc-p6Gag-GFP11 This paper N/A
pBbsr-VSV-G-NJ-GFP11 This paper N/A
pBbsr-VSV-G-Myc-Cre This paper N/A
pCMV4-BlaM-Vpr Neil King/University of Washington N/A
pBbsr-BlaM-Vpr-GFP1-10 This paper N/A
pBbsr-Cre-GFP1-10 This paper N/A
EGFP-hAgo2 Leung et. al., 2006 Addgene plasmid #21981
pBbsr-AGO2-GFP1-10 This paper N/A
pBS-elav-1 Wang et al., 2010 Addgene plasmid #26130
pBbsr-Elav1-GFP1-10 This paper N/A
pX602-AAV-TBG::NLS-SaCas9-NLS-HA-OLLAS-
bGHpA;U6::BsaI-sgRNA
Ran et al., 2015 Addgene plasmid #61593
pBbsr-NLS-SaCas9-NLS-HA-GFP1-10 This paper N/A
pBbsr-CD9-GFP11 This paper N/A
pBbsr-CD81-GFP11 This paper N/A
Lenti-CRISPR/Cas9-sgMunc13-4 This paper N/A
pLKO-PINK1-shRNA Zhang, et al, 2014 N/A
LentiCRISPR-EGFP sgRNA 1 Shalem et al., 2014 Addgene plasmid #51760
pEntry-bGH-U6-(SaCas9)-sgPINK1 This paper N/A
pEntry-bGH-U6-(SaCas9)-sgEGFP This paper N/A
pEntry-bGH-U6-(SaCas9)-sgPCSK9 This paper N/A
pEntry-bGH-U6-(SaCas9)-sgRosa26 This paper N/A
pBbsr-CD47-Myc-GFP11 This paper N/A
pBbsr-CD47nanobody-Myc-GFP11 This paper N/A
Cell Lines
293T ATCC Cat# CRL-1573
293ColorSwitch This paper N/A
HeLa ATCC Cat# CCL-2
HeLa-Venus-Parkin-RFP-Smac Zhang, et al., 2014 N/A
HeLa-PINK1-EGFP Zhang, et al., 2017 N/A
Antibodies
Mouse anti-VSV-G (8G5F11) Kerafast Cat# EB0010; RRID: AB_2811223
Mouse anti-BlaM Abcam Cat# ab12251; RRID: AB_298974
Rabbit anti-GFP Cell Signaling Technology Cat# 2956; RRID: AB_1196615
Mouse anti-Myc tag Cell Signaling Technology 9B11, Cat#2276
Rabbit anti-CD9 Cell Signaling Technology Cat# 13174; RRID: AB_2798139
Rabbit anti-Flotillin Cell Signaling Technology Cat# 18634; RRID: AB_2773040
Rabbit anti-GM130 Cell Signaling Technology Cat# 12480; RRID: AB_2797933
Mouse anti-Actinin4 Santa Cruz Biotechnology Cat# sc-166524; RRID: AB_2257995
(Continued on next page)
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Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Mouse anti-TSG101 Santa Cruz Biotechnology Cat# sc-7964; RRID: AB_671392
Rabbit anti-PINK1 Cell Signaling Technology Cat# 6946; RRID: AB_11179069
Rabbit anti-Munc13-4 R&D Systems Cat# MAB8966
Rabbit anti-Annexin V Cell Signaling Technology Cat# 8555; RRID: AB_10950499
Mouse anti-GAPDH Santa Cruz Biotechnology Cat# sc-47724; RRID: AB_627678
Mouse anti-b-actin Santa Cruz Biotechnology Cat# sc-47778 HRP; RRID: AB_2714189
Mouse anti-PCSK9 R&D systems From the ELISA Kit
Anti-mouse IgG, HRP-linked Antibody Cell Signaling Technology Cat# 7076; RRID: AB_330924
Anti-Rabbit IgG, HRP-linked Antibody Cell Signaling Technology Cat# 7074; RRID: AB_2099233
Goat anti-Mouse IgG/M Gold 6nm Electron Microscopy Sciences Cat# 25123
Chemicals and Proteins
PEI, Polyethylenimine Sigma-Aldrich CAS#9002-98-6
CCCP, Carbonyl cyanide m-chlorophenyl hydrazone Sigma-Aldrich CAS#555-60-2
GW4869 Cayman Chemical Cat# 13127
Recombinant (E. Coli) rGFP protein PROSPEC Cat# pro-687-a
Protein-G Magnetic beads Thermo Scientific Cat# 88847
Protein-G Agarose beads Thermo Scientific Cat# 20397
Exosome Human CD9 Isolation kit Life Technologies Cat# 10614D
Aldehyde sulfate beads Invitrogen Aldehyde/Sulfate latex, 4% w/v 4mm
Primers and sgRNA
50-CACCGCCTGGAGGTGACAAAGAGCA-30 Invitrogen PINK1, Forward
50-AAACTGCTCTTTGTCACCTCCAGGC-30 Invitrogen PINK1, Reverse
50-CGCTGCTGCTGCGCTTCA-30 Invitrogen PINK1Ex1, Forward
50-CTGCTCCATACTCCCCAGCC-30 Invitrogen PINK1Ex3, Reverse
50-GTCTCCATAATCAGACACCT-30 Invitrogen PINK1Int2, Forward
50-GGATGGTGAACTAACCAATC-30 Invitrogen PINK1Int3, Reverse
50-GATGCCACTTTACTTCGGAGGA-30 Invitrogen mPCSK9, Forward
50-AGGAGGATTGGAGTGGGGATTA-30 Invitrogen mPCSK9, Reverse
50-CACCGAGGACCGCCCTGGGCCTGG-30 Invitrogen sgRosa26 Forward
50-AAACCCAGGCCCAGGGCGGTCCTC-30 Invitrogen sgRosa26 Reverse
50-CACCGCAGCCACGCAGAGCA-30 Invitrogen sgmPCSK9 Forward
50-AAACTGCTCTTTGTCACCTCCAGGC-30 Invitrogen sgmPCSK9 Reverse
50-CACCGCCTGGAGGTGACAAAGAGCA-30 Invitrogen sgPINK1 Forward
50-AAACTGCTCTTTGTCACCTCAGGC-30 Invitrogen sgPINK1 Reverse
50- CACCGCGAGACCTTCATCCTGTACG-30 Invitrogen sgMunc13-4 Forward
50- AAACCGTACAGGATGAAGGTCTCGC-30 Invitrogen sgMunc13-4 Reverse
50-CACCGTCGTGCTGCTTCATGTGGT-30 Invitrogen sgEGFP Forward
50-AAACACCACATGAAGCAGCACGAC-30 Invitrogen sgEGFP Reverse
Commercial Kits
GeneBLAzer In Vivo Detection Kit Invitrogen Lot# 1906803
Mouse Proprotein Convertase 9/PCSK9 Quantikine
ELISA Kit
R&D systems Cat# MPC900
Mouse LDL-Cholesterol Kit Crystal Chem Cat# 79980
ExoFlow-ONE EV Labeling Kit for Flow Cytometry SBI System Biosciences Cat# EXOFXXXA-1
TOPO TA-Cloning kit Invitrogen Lot# 1952884
Software
ImageJ NIH N/A
GraphPad Prism 7 GraphPad Software N/A
Blender The Blender Foundation N/A
(Continued on next page)
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RESOURCE AVAILABILITY
Lead Contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Xuedong
Liu (Xuedong.Liu@colorado.edu).
Materials Availability
All unique generated in this study will be made available on request, but we may require a payment and/or a completed Materials
Transfer Agreement if there is potential for commercial application.
Data and Code Availability
Label-free quantitative mass spectrometry data are provided in Table S2. All other relevant data are available from corresponding
author (X.L.) upon request.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animals
All mouse experiments were performed according to the protocol (No. 2667) approved by the IACUC office of the University of Col-
orado Boulder and the NIH guidelines. Female BALB/cmice (4 to 6weeks old) from The Jackson Laboratory were used in Gectosome
clearance and genome editing experiments.
Cell Culture
293T, 293ColorSwitch, RAW264.7, andHeLa cell lines were obtained from the American Type Culture Collection (ATCC). All cell lines
were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% FBS, 2 mM glutamine, 100 U/Ml penicillin,
and 100mg/mL streptomycin at 37Cwith 5%CO2 incubation. 293T cells were used as theGectosome producer cells. HeLa-Venus-
Parkin-RFP-Smac and HeLa-PINK1-EGFP have been reported (Zhang et al., 2014, 2015, 2017). HeLa cells stably expressing
Munc13-4 sgRNA were created using lentiviral particles from 293T cells transfected with lentiviral vector pLentiCRISPRv2-
Munc13-4 sgRNA with three co-packaging plasmids (Zhang et al., 2014, 2015, 2017). 293ColorSwitch cell line was constructed




A custom-built plasmid vector, called pBbsr-DEST, which contains the Gateway recombination sites, piggyback recombination
sites, and IRES-blasticidin, was used for expressing genes in mammalian cells. pBbsr-DEST was constructed using the backbone
of pPBbsr2 (a gift of Aoki andMatsuda) (Komatsu et al., 2011). For expression of the guide RNAs for SaCas9 or LwaCas13, platform-
specific scaffolds were subcloned into an entry vector derived from pENTR221 (Invitrogen). Detailed maps of these parental vectors
are available upon request. GFP11 and GFP1-10 fragments were first subcloned into pENTR and then recombined into pBbsr-DEST
to yield pBbsr-GFP11 and pBbsr-GFP1-10 with stuffers. The cDNAs of VSV-G, VSV-G-NJ, CD9, CD81, CD47, CD47nb, HIV-
p6Gag,GFP1-10 and GFP11 were obtained by gene synthesis (Twist Biosciences or BioBasic) and subcloned into pBbsr-GFP11.
The cDNAs of BlaM-Vpr, Cre, AGO2, Elav and SaCas9 were subcloned into pBbsr-GFP1-10 from their source vectors. sgRNA
expression vectors for PCSK9, Rosa26, PINK1, EGFP and Cre were constructed by inserting oligonucleotides synthesized into pEn-
try-U6-(SaCas9). siRNA PINK1 was synthesized by Dharmacon. sgMunc13-4 expression vector was constructed by inserting an-
nealed oligos corresponding to the region of exon 6 in pLentiCRISPRv2-Puro.
Recombinant Protein Expression
Recombinant His-Flag-tagged Cre protein was expressed and purified in E. coli using pET28a vector and stored in a protein buffer
(25mMHEPES [pH 7.4], 150mMKCl, 10%glycerol, and 1mMDTT) (Yu et al., 2015). The recombinant Cre activity was determined as
1U/50ng according to the protocol from NEB (https://www.neb.com/protocols/2014/02/12/protocol-for-cre-recombinase-m0298).
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
BD FACSDiva BD Biosciences N/A
DAVID Bioinformatics Resources 6.8 NIAID/NIH N/A
Deposited Data
Proteomics data are reported in Table S2 This paper N/A
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Production of Gectosomes
293T cells were seeded into 100mmdishes and allowed to reach 70–80%confluence before transfection with polyethylenimine (PEI,
3 mL of PEI per mg DNA). Six hours after transfection, the medium was replaced with 10 mL of fresh DMEM. Supernatants were
collected at 24 h or 48 h after transfection. For large scale production of Gectosomes for in vivo studies, Freestyle 293 Expression
Medium (Thermo Fisher) was used instead of DMEM. The culture supernatants were harvested 48 h after transfection and then sub-
ject to centrifugation at 2,000 3 g for 10 min. The resultant supernatant is referred to as the crude Gectosomes.
Flow Cytometric Analysis of Gectosomes
The size distribution of Gectosomes by flow cytometry using FACSAria Fusion Cell Sorter (BD). The crude Gectosomes were run on a
FACSAria Fusion (Rate=20000 events/second) under FITC channel. The size reference beads from a kit (ExoFlow-ONE EV Labeling
Kit for Flow Cytometry, SBI System Biosciences) were used as a standard size control. DMEM with 10% FBS, conditional control
cultural supernatant, and the crude Gectosomes were diluted with ultrafiltered PBS (100KDa cutoff Amicon Ultra-15 Centrifugal Fil-
ter) to 1:100 and then submitted to flow cytometric analysis. 100,000 particles were collected for each sample. The gate was plotted
according to the standard size reference beads where there were two groups colored with FITC. FITC-110 and FITC-500 are referred
to as 110nm and 500nm size beads. The ratio of GFP-positive Gectosomes was analyzed with BD FACSDiva software.
Particle Size and Concentration Measurement by Nanoparticle Tracking Analysis (NTA)
NanoSight NS300 (NanoSight Ltd., UK) equipped with a high sensitivity sCMOS camera and NanoSight NTA 3.0 software was used
to measure the size distribution and concentration of total particles of extracellular vesicles following the instructions of the manu-
facturer. The measurement parameters were as follows: temperature ranging from 21 to 23.6C; viscosity between 0.9 and 0.965 cP,
measurement time 60s, and 3 technical repeats (n=3). The measurement threshold was set at a similar level for all test samples. The
data of total particles were obtained under the clear scatter measurement. We used 488 nm fluorescent filters to collect the data
specific for fluorescent Gectosomes or exosomes. The results were shown as the mean sizes of particles plus standard deviations
of three repeats.
Gectosome Release Assay
To confirm the release of Gectosomes from producer cells, we seeded 293T cells into a 6-well plate and transfected at 70–80%
confluence with 1mg of pBbsr-VSV-G-GFP11 plus 2 mg pBbsr-BlaM-Vpr-GFP1-10 or Cre-GFP1-10 or AGO2-GFP1-10 or SaCas9-
GFP1-10 using PEI. Themediawere replacedwith 2mL of freshDMEMafter 6 hr. Cell pellets and culture supernatants were collected
48 hr later. After removal of cell debris through centrifugation at 2,000 3 g for 10 min, the released particles were collected through
ultra-centrifugation with a 20% sucrose cushion for 90 min at 100,000 3 g 4C. The resultant pellets enriched with EVs were resus-
pended in 50uL of lysis buffer (50 mM Tris [pH 7.4], 150 mM NaCl, 1% Triton X-100, and a protease inhibitor cocktail (Roche)). The
corresponding cell pellets were lysed for 30min on ice in 100 mL of lysis buffer and clarified by centrifugation for 5min at 12,000 rpm at
4C to separate into the Triton-soluble and -insoluble cellular fractions. The EVs, Triton-soluble, and Triton-insoluble fractions were
subjected to SDS-PAGE and immunoblotting analysis.
Immunoblotting Analysis
Protein concentration for cell extracts and vesicleswasmeasured using the BCA assay (Thermo Fisher). Equivalent amounts of proteins
were boiled in Laemmli sample buffer, resolved on 12% SDS-PAGE gels, and transferred to a 0.22mm nitrocellulose membrane. Mem-
branes were blocked for 1 h in 5% non-fat dry milk (Nestle Carnation) or 5% bovine serum albumin depending on the primary antibody
used. The filters were incubated with specific antibodies in Tris-buffered saline, 0.1% Tween 20 (TBST) overnight at 4C. Antibodies
used for Western blotting were as follows: anti-VSV-G (Mouse, 1:1000, Kerafast); anti-GFP (Rabbit, 1:1000, Cell Signaling Technology);
anti-BlaM (Mouse, 1:1000, Abcam); anti-PINK1(Rabbit, 1:1000, Cell Signaling Technology); anti-GAPDH (1:2000, Santa Cruz Biotech-
nology); anti-CD9 (Rabbit, 1:1000, Cell Signaling Technology); anti-GM130 (Mouse, 1:1000, Cell Signaling Technology); anti-b-actin
(Mouse, 1:2000, Santa Cruz Biotechnology); anti-Actinin4 (Mouse, 1:1000, Santa Cruz Biotechnology); anti-TSG101 (Mouse, 1:1000,
Santa Cruz Biotechnology); anti-Annexin V (Mouse, 1:1000, Cell Signaling Technology); anti-Flotillin (Mouse, 1:1000, Cell Signaling
Technology). Munc13-4 antibody (Rabbit, 1:1000, R&D systems). For chemiluminescence detection of proteins, HRP-conjugated
anti-rabbit IgG (Cell Signaling Technology), and anti-mouse IgG (Cell Signaling Technology) secondary antibodies, and SuperSignal
West Dura Substrate (Fisher Scientific) were used. ImageQuant LAS 4000 (GE HealthCare) was used to acquire images of the blots.
For quantitative immunoblotting experiments to determine the amount of VSV-G, Cre, and BlaM in Gectosomes, recombinant GFP
protein (pro-687) was purchased from ProSpec, and recombinant b-lactamase (RP-431) was purchased from Alpha Diagnostic In-
ternational. Recombinant Cre was prepared as described above. Serial dilutions of each recombinant protein were quantified by
Coomassie blue staining along with a known amount of BSA to derive a standard curve for each protein.
BlaM and Cre Protein Cellular Uptake Assays
The b-lactamase (BlaM) cellular uptake assay was performed following the reported procedure (Votteler et al., 2016). Briefly, the indi-
cated number of Gectosomes was incubated with HeLa or the mentioned cell lines seeded in 6-well plates for 16 hr or indicated time
points. Cells were trypsinized, harvested, and spun at 1000 rpm for 5 min. Cell pellets were resuspended using 50 mL of CCF2-AM
labeling solution prepared according to the manufacturer’s instructions supplied with GeneBLAzer In Vivo Detection Kit (Thermo
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Fisher Scientific). Cells were labeled for 1 h at 25C and then washed once with DMEM medium. The labeled cells in 500 mL fresh
DMEMmediumwere analyzed by flow cytometry using BDFACSCelesta (BDBiosciences). 10,000 cells were collected for each sam-
ple. The fluorescence profiles in 488 nm and 405 nm channels were acquired and plotted using BD FACSDiva software. The mean
percentages and standard deviations of three repeats were recorded.
For measuring Cre cellular uptake, 293ColorSwitch cells seeded on 6-well plates were used as target cells and incubated the indi-
cated number of extracellular vesicles for 48 hr or indicated times. Following the incubation, cells were trypsinized, harvested, and
scanned in 595 nm and 488 nm channels by flow cytometry using BD FACSCelesta (BD Biosciences). 10,000 cells were collected for
each sample. The results were plotted with BD FACSDiva, and the mean percentages of green cells with standard deviations were
recorded with three replicates (n=3).
Purification and Immobilization of the VSV-G Antibody
To purify the anti-VSV-G antibody, hybridoma cell line 8G5F11 (a gift of Douglas Lyles) was cultured in RPMI1640 for 3 days. The
resultant supernatant was harvested by centrifugation at 2,0003 g for 5 min and subsequently filtered using a 0.2 mmfilter to remove
smaller cell debris. The cleared supernatant was incubated with Protein G-Agarose beads or Protein G-magnetic beads (Thermo
Fisher) overnight. The antibody-bound beads were washed with PBS for 5 min three times, eluted with 100 mL 0.1M Glycine [pH
2.7], and neutralized with 1M Tris [pH9.5].
For conjugation of the VSV-G antibody to Protein G-Agarose beads or Protein G-magnetic beads, beads were incubated with the
purified antibody overnight at 4oC and then washedwith PBS to remove the unbound antibodies. Freshlymade DMP solution (13mg/
mL Dimethylpimelimidate in Wash buffer, pH8-9) was added to beads at 1:1 ratio, and the mixture was rotated for 30 min at the room
temperature. The conjugated beads were washed three times with the Wash buffer (0.2 M triethanolamine in PBS) at room temper-
ature for 5min per cycle. The conjugated beads were resuspended in PBS, and the labeling reaction was stopped by adding an equal
volume of the quench buffer (50 mM ethanolamine in PBS). The beads were washed with 0.1 M glycine [pH 2.7] for 10 min twice and
stored in PBS with 20% ethanol at 4C until further use.
Isolation and Purification of Gectosomes
Isolation of EVs by Ultracentrifugation (UC)
The conditionedmedium collected from cells growing on 100mmplates was first cleared by low-speed centrifugation at 2,0003g for
10min (2K sample) to remove cell debris. The supernatant was centrifuged at 10,0003g at 4C for 30 min (10k pellet), transferred to
new tubes, and ultracentrifuged at 100,0003g in an SW41Ti (Beckman Coulter) at 4C for 90 min (100k pellet).
Isolation of Gectosomes by Immunocapture
Cell conditioned medium was collected from confluent control or transfected 293T cells grown in Freestyle 293 Expression Medium
on 100mmculture dishes at 24 hr or 48 hr after transfection. Themedium cleared by centrifugation at 10,0003g for 30min at 4Cwas
incubated with magnetic beads or agarose beads containing the crosslinked 8G5F11 VSV-G antibody (8G5F11) at 4C overnight.
Beads bound with Gectosomes were washed with PBS for 5 min three times. Gectosomes were eluted with 0.1M Glycine [pH
2.7] and then neutralized with 1M Tris [pH9.5].
Purification of Gectosomes
0.5 mL of the cell-conditioned medium was processed as the above, except that supernatant from the 10,000 3g spin was loaded
onto IZON qEVoriginal column (IZON Science). Fractions (500 mL each) were collected using an Automatic Fraction Collector (IZON
Science). Gectosomes were eluted in fractions 2 and 3, as determined by flow cytometry and immunoblotting analyses. Fraction 2
and 3 were combined and incubated with magnetic beads containing the crosslinked 8G5F11 VSV-G antibody. Gectosomes were
eluted with 0.1M Glycine [pH3.7] and then neutralized with 1M Tris [pH9.5].
Fluorescence Microscopy
293T cells were seeded in a 96-well plate with glass bottom at 50% confluence and then transfected with plasmids encoding the split
GFP system. 24 hours after transfection, cells were fixed with 2% paraformaldehyde in PBS containing DAPI (1.5 mg/ml DAPI). For
imaging Gectosomes uptake, HeLa cells were incubated with Gectosomes for indicated times before fixation with 2% paraformal-
dehyde in PBS containing DAPI (1.5 mg/ml DAPI). Cells were stained with indicated primary and secondary antibodies before they
were imaged with a laser scanning confocal microscope (Nikon A1R).
For the fluorescence switch imaging, 293ColorSwitch cells were seeded in a 96-well plate with glass bottom at 50% confluence
before incubation with VSV-G/Cre Gectosomes. After 48 hours, cells were stainedwith Hoechst 33342 and imaged described above.
Negative Stain Transmission Electron Microscopy and Immunogold Labeling
TEM imaging and sample preparation were performed at the ElectronMicroscopy Services Core Facility of the University of Colorado
Boulder.
Negative Stain TEM
Purified sfGFP and Cre Gectosomes through immunoaffinity procedure were applied to the negative stain. Briefly, 5 mL of the sam-
ples were firstly fixed in 4% paraformaldehyde for 1 hour, applied on a discharged, carbon-coated 400-mesh copper grid, and left it
on for 3-5 minutes. The grid was washed in 1mM EDTA, and then 10 mL 0.75% uranyl formate is to be used for 1 minute for staining.
The grid was subjected to TEM imaging.
ll
Technology
Developmental Cell 55, 1–18.e1–e9, December 21, 2020 e5
Please cite this article in press as: Zhang et al., Programmable Extracellular Vesicles for Macromolecule Delivery and Genome Modifications, Devel-
opmental Cell (2020), https://doi.org/10.1016/j.devcel.2020.11.007
Immunogold Labeling TEM
Briefly, for immunogold labeling with anti-VSV-G, purified Gectosomes through immunoaffinity procedure were fixed for 1 h in 4%
paraformaldehyde and then applied to a discharged, carbon-coated 400-mesh grid. The grids were then put onto a droplet of 1M
Ammonium Chloride for 30 minutes. The samples on the grid were applied to immunogold labeling. The grids were rinsed for
5 min on large droplets of TBS-Tween (50mM TBS, 0.05% Tween 20, [pH 7.6]) for three times. The grids were incubated in block
solution (1% BSA, 3% normal serum, 0.1% Fish Gelatin, 0.05% Sodium Azide in 0.05M TBS, [pH 7.6]) for 30 minutes. Then the grids
were put into droplets of VSV-G antibody (1:50) (or mouse serum as control) diluted in block solution for 1 hour at room temperature.
After rinsed the grids in large droplets of TBS-Tween for 5min for three times, the grids were incubated in droplets of goat anti-mouse
IgG/M 6nm (1:40) for 1 hour at room temperature. The samples on the grids were rinsed in droplets of TBS-Tween for 5 min three
times. Lastly, a negative stain was performed as mentioned above. The images were recorded on a 120 kV Tecnai G2 Spirit trans-
mission electron microscope at 52,000 3 magnification.
Recombinant Cre Liposome Preparation
The preparation of recombinant Cre liposome was performed following the published procedure (Yu et al., 2018). Lipids used in this
work were purchased from Avanti Polar Lipids. Briefly, 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (POPC), 1-palmitoyl-2-
oleoyl-sn-glycerol-3-phosphoethanolamine (POPE), 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphoserine (POPS), and cholesterol
were mixed in a molar ratio of 60:20:10:10. Cre proteoliposomes were prepared by the detergent dilution method. Complete deter-
gent removal was achieved by overnight dialysis using Novagen dialysis tubes against the reconstitution buffer (25 mM HEPES [pH
7.4], 100 mM KCl, 10% glycerol, and 1 mM DTT) followed by liposome flotation on a Nycodenz gradient (Yu et al., 2019). The final
concentration of Cre encapsulated in the liposome was determined by immunoblotting analysis using a serial dilution of a known
amount of Cre as the standard.
Mass Spectrometry Analysis
Gectosomes immunocaptured on beads were boiled with 30 mL 1%SDS in 100 mMTris-HCl [pH7.3] for 10min and then submitted to
mass spectrometry analysis. The samples were reduced and alkylated in 50 mM Tris-HCl, pH 8.5, containing 4% (w/v) SDS, 10 mM
Tris(2-carboxyethylphosphine) (TCEP) and 40 mM chloroacetamide by boiling at 95C for 10 min. Samples were then digested using
the SP3 method (Hughes et al., 2014). Briefly, carboxylate-functionalized speedbeads (GE Life Sciences) were added to the extracts
and then acetonitrile was added to 80% (v/v) to precipitate proteins onto the beads. The beads were washed twice with 80% (v/v)
ethanol and twice with 100% acetonitrile. Proteins were digested on the beads in 20 mL 50 mM Tris-HCl [pH 8.5] and 0.5 mg Lys-C/
Trypsin (Promega) incubating at 37C for 18 hours with shaking at 1000 rpm. Digestion buffer was removed by adding acetonitrile to
95% (v/v) again, precipitating tryptic peptides onto the beads, followed by washing the beads once with acetonitrile. Peptides were
removed from the beads in 50 mL 1% (v/v) trifluoroacetic acid and 3% (v/v) acetonitrile, then dried in a vacuum concentrator and
stored at -20C.
Sampleswere suspended in 15 mL 0.1% (v/v) trifluoroacetic acid and 3% (v/v) acetonitrile then 5 mLwas directly injected onto aC18
1.7 mm, 130 Å, 75 mm X 250 mmM-class column (Waters) using a Thermo Scientific Ultimate 3000 RSLCnano UPLC. Peptides were
eluted at 300 nL/minute using a gradient from 3% to 7% acetonitrile in 4 min, then 7% to 24% acetonitrile over 36 min into a Q-Ex-
active HF-X mass spectrometer (Thermo Scientific). Precursor mass spectra (MS1) were acquired at a resolution of 60,000 from 380
to 1580 m/z with an AGC target of 3x106 and a maximum injection time of 45 ms. Precursor peptide ion isolation width for MS2 frag-
ment scans was 1.4 m/z sequencing the top 12 most intense ions. All MS2 sequencing was performed using higher-energy collision
dissociation (HCD) at 27% collision energy and scanning at a resolution of 15,000. An AGC target of 105 and 40 s maximum injection
time was used for MS2 scans. Dynamic exclusion was set for 30 seconds with a mass tolerance of +/–10 ppm. MS data files were
searched against the Uniprot human database downloaded 11/13/2019 with three additional sequences for VSV-G/GFP, b-lacta-
mase and Cre using Maxquant version 1.6.3.4. Cysteine carbamidomethylation was set as a fixed modification, while methionine
oxidation and protein N-terminal acetylation were set as variable modifications. All peptides and proteins were filtered at a 1% false
discovery rate (FDR). Proteins identified by one or more specific peptides in either VB or VCB samples (Q<0.001) were included in
Table S2 for the analysis.
RNA Interference by Gectosomes
Gectosomes loaded with PINK1 shRNA were produced by transient transfection of 293T cells with PINK1 shRNA plasmid (Zhang
et al., 2014, 2017) along with expression plasmids VSV-G-GFP11 and AGO2-GFP1-10 or Elav-GFP1-10. The conditional culture su-
pernatant containing Gectosomes (~3x108 particles/mL) was harvested, and 2 mL was incubated with target HeLa-Venus-Parkin-
RFP-Smac cells (~3x105 cells/ well in a 6-well plate). After 24 hours, the culture supernatant was replaced with 2 mL of fresh media.
After 3 days, Parkin localization on mitochondria in HeLa-Venus-Parkin-RFP-Smac cells in response to CCCP treatment was
analyzed by method described below. Total RNAs were isolated using the Trizol method (Thermo Fisher Scientific). The levels of
PINK1 mRNA was measured by RT-qPCR analysis. The primers used in RT-qPCR were listed below: 5’-CACCGCCTGGAGGTGA
CAAAGAGCA-3’ (PINK1, Forward), 5’-AAACTGCTCTTTGTCACCTCCAGGC-3’ (PINK1, Reverse). GAPDH gene was used as the
control. The GAPDH primers used were listed below: 5’- GAAGGTGAAGGTCGGAGT-3’ (Forward) and 5’- GAAGATGGTGATGG
GATTTC-3’ (Reverse). Immunoblotting was used to probe the PINK1 protein level.
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Genome Editing with CRISPR/Cas9 Gectosomes
Gectosomes encapsulated with SaCas9-sgPINK1 (or mouse sgPCSK9) were produced by transient transfection of 293T cells with
VSV-G-GFP11, SaCas9-GFP1-10 with guide RNA encoding plasmid sgPINK1 or mouse sgPCSK9. For PINK1 editing in human cells,
the conditioned culture supernatant containing the indicated Gectosomes (108 particles/mL) was harvested, and 2 mL of the super-
natant was incubated with HeLa-Venus-Parkin-RFP-Smac and HeLa-PINK1-EGFP cells (3x105 cells/well in a 6-well plate). After 24
hours, the culture supernatant was replaced with 2 mL of fresh media. After treatment for five days, Parkin localization on mitochon-
dria, protein levels, and mRNA levels of PINK1-EGFP in HeLa-Venus-Parkin-RFP-Smac and HeLa-PINK1-EGFP cells as described
above. For PCKS9 gene editing in mouse cells, MEF cells were incubated with Gectosomes loaded with SaCas9 and sgPCSK9.
To determine whether PINK1 or PCSK9 was edited in cells exposed to Gectosomes, the genomic DNA of the treated cells was
extracted using the Blood and Tissue DNA Extraction kit (Qiagen) following the manufacturer’s instructions. The primer sequences
for PINK1 gene target are: 5’- CGCTGCTGCTGCGCTTCA-3’ (PINK1Ex1, Forward, for Exon PCR) and 5’- CTGCTCCATACTCCC
CAGCC-3’ (PINK1Ex3, Reverse, for Exon PCR), 5’- GTCTCCATAATCAGACACCT-3’ (PINK1Int2, Forward, for intron PCR) and 5’-
GGATGGTGAACTAACCAATC-3’ (PINK1Int3, Reverse, for intro PCR), 5’-GATGCCACTTTACTTCGGAGGA-3’ (mPCSK9, Forward)
and 5’-AGGAGGATTGGAGTGGGGATTA-3’(mPCSK9, Reverse). PCR products were recovered and cloned using a TOPO TA Clon-
ing Kit (Invitrogen). The colonies with insert fragments were sequenced and aligned with wild type genomic sequences, respectively.
Gectosome Clearance by Macrophage Cells
Gectosomes with CD47 or CD47nanobody were prepared from 293T cells seeded on 100 mm plates by transfecting 5 mg VSV-G-
GFP11 plus 10 mg BlaM-Vpr-GFP1-10 with 5 mg CD47-GFP11 or 5 mg CD47nanobody-GFP11 plasmids. Gectosomes were har-
vested 48 hr post-transfection and cleaned up at 2,000 3 g for 10min. Next, Gectosomes were incubated with RAW 264.7 cells
for the indicated period. RAW 264.7 cells were subsequently removed to recover the supernatants, which were subsequently incu-
bated with HeLa cells for 16 hr before the BlaM activity was measured by flow cytometry, as described above.
To directly measure the depletion of Gectosomes by macrophage, the particles were coupled to Aldehyde/Sulfate beads using a
protocol (Thery et al., 2006) for flow cytometric analysis. Briefly, the supernatants recovered after incubation with RAW 264.7 cells
were ultracentrifuged for 1.5 hr at 100,0003g at 4C twice. The pellets were then resuspended in 200 mL PBS plus 10 mL of Aldehyde
sulfate beads (Aldehyde/Sulfate latex, 4%w/v 4 mm, Invitrogen). 600 mL of PBS was then added to the mixtures and kept at 4C on a
tumbler overnight. Then 1M glycine (400 mL) was added to the mixture and incubated at room temperature for 1 hr. Beads were
collected by brief centrifugation and washed three times with PBS plus 10% FBS before resuspended in 1 mL PBS with 10%
FBS. The fluorescence intensity of Gectosomes immobilized on the beads was measured by flow cytometry.
Gectosome Clearance in Mice
To measure the Gectosome level in circulation in vivo, female BALB/c mice (4 to 6 weeks old) were injected intravenously with sfGFP
Gectosomes produced with or without CD47 in 293T cells. The concentration of sfGFP positive Gectosomes in the supernatant was
determined byNTA. Gectosomeswere buffer-exchanged and concentrated to 1010 particles in 150 mL of PBS using ultrafiltration with
the 100KDa cutoff Amicon Ultra-15 Centrifugal Filters). Concentrated Gectosomes were injected into BALB/c mouse (3 mice each
group) through the tail vein. Three hours after injection, the injected mice were sacrificed to collect the EDTA-anticoagulated blood
(150 mL) frommouse orbit. The blood samples were kept at room temperature for 1 hr prior to collecting the plasma by centrifugation
at 3,000 rpm for 10 min at 4C. Plasma (150 mL) was diluted to 5ml with PBS and ultracentrifuged 1.5 hr at 100,0003g at 4C twice.
The pellet was resuspended in PBS and mixed with aldehyde sulfate beads as described above. The rate of Gectosome depletion
was measured by flow cytometry.
Genome Editing in Mice
Female BALB/c mice (4 to 6 weeks old) were ordered from The Jackson Laboratory. For the investigation of whether Gectosome
delivery of the SaCas9-sgPCSK9 gene editing complex, the control and PCKS9Gectosomeswere prepared by transient transfection
of 293T cells growing in Freestyle 293 Expression Medium. Gectosomes were concentrated approximately 100-fold by ultrafiltration
using 100KDa cutoff Amicon Ultra-15 Centrifugal Filter Unit. Gectosomes were injected into 4-week-old female BALB/c mice via the
tail vein. All dosages of Gectosomes were adjusted to 150 mL containing approximately 109 fluorescent Gectosomes in sterile phos-
phate-buffered saline. Mice received 109 particles/150 mL each tail vein injection for four times at 48 h of interval. For the measure-
ment of the serum levels of PCSK9 and LDL-cholesterol, animals fasted overnight for 15 hr before blood collection by saphenous vein
bleeds. Approximately 50mL bloodwas collected from eachmouse every 10 days after injection. The serumwas collected and stored
at 20C for subsequent analysis. Thirty days after injections all mice were sacrificed by carbon dioxide inhalation followed by cer-
vical dislocation, and liver tissue samples were collected and stored at -80C for subsequent DNA or protein extraction.
The level of PCSK9 protein in serum was determined by ELISA using a commercial ELISA kit (Mouse Proprotein Convertase 9/
PCSK9 Quantikine ELISA Kit, MPC-900, R&D Systems) following the manufacturer’s instructions. Serum LDL-cholesterol level
was measured using a Mouse LDL-Cholesterol kit (Crystal Chem) per the manufacturer’s instructions. Genomic DNA from mouse
livers was isolated, and the PCSK9 gene-editing analysis was carried out as described above.
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Mathematical Modeling of Gectosomes
Estimation of Protein Numbers in Gectosome
To determinate the abundance of VSV-G-GFP11 and Cre-GFP1-10 in Gectosome, we performed quantitative Western blot exper-
iments andmeasured the expressed amount of VSV-G-GFP11, Cre-GFP1-10 proteins with recombinant protein stands. As shown in
Figure S4E, there is about 7.47310-7 ng VSV-G-GFP11, 9.73310-8 ng Cre-GFP1-10 present per Gectosome when 293T cells were
transfected with 1 mg VSV-G-GFP11, 2 mg Cre-GFP1-10, and 1 mg BlaM plasmids.




3 6:023 1023 = 5:623 103 molecules: (Equation 1)
#CreGFP1 10= 9:733 10
8 3 109
6:283 104
3 6:023 1023 = 9:333 102 molecules: (Equation 2)
3D Modeling for the Space-Filling of VSV-G-GFP11 and Cre-GFP1-10 Proteins in Gectosomes
The average measured diameter of single Cre Gectosome vesicles in this study is about 185 nm (Figure S2B). Here we assume that
Gectosome vesicles are spherical. Considering that the bilayer thickness is about 2.5-3.5 nm and one side of the lipid head is about
1nm (Andersen and Koeppe, 2007), we estimate that the membrane thickness of a Gectosome is about 5 nm.
If we model VSV-G protein into the membrane in the Orientations of Proteins in Membranes (OPM) database (Lomize et al., 2006),
the VSV-G protein attaches to the outer membrane surface of the vesicle. Cre-GFP1-10 will form a complex with VSV-G-GFP11
through an assumed irreversible complementation process; they are attached to the inner membrane of the Gectosome. We
retrieved the protein structures of VSV-G monomer protein structure (PDB ID: 5I2S), sfGFP protein structure (PDB ID: 2B3P) and
Cre recombinasemonomer (PDB ID: 1NZB) in Blender with ePMV plugin (Johnson et al., 2011), which show the following dimensions













Figure S4E illustrates the relative size and orientation of different protein structures in a Gectosome.
The Occupancy of VSV-G Proteins at the Surface of Gectosomes
Based on the structure of VSV-G (PDB ID: 5I2S) monomer, the center of VSV-G was measured with a dimension of 5 nm (x-axis) and
4 nm (y-axis) and it is about 100 nm away from the center of Gectosome. We approximate this area as a circle with a diameter of






4pð100Þ2 = 71:1% (Equation 3)
The Occupancy of Cre-GFP Proteins Close to the Inner Membrane of a Gectosome
Based on the parameters shown in Figure S4E, we can estimate the volume of the intra-Gectosome sphere (Vti ; excludingmembrane)




pð77:1+ 5+ 5:4Þ3  4
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= 2:813 106 ðnmÞ3 (Equation 5)
ll
Technology
e8 Developmental Cell 55, 1–18.e1–e9, December 21, 2020
Please cite this article in press as: Zhang et al., Programmable Extracellular Vesicles for Macromolecule Delivery and Genome Modifications, Devel-
opmental Cell (2020), https://doi.org/10.1016/j.devcel.2020.11.007
To estimate the space that is occupied by Cre and complemented GFP complex, we use protein bounding volume (Fonseca and
Winter, 2012).
The bounding volume for one Cre monomer and one sfGFP protein is
VCreGFPb = 7:43 6:53 5:4+ 5:33 4:835= 387 ðnmÞ3 (Equation 6)
The total bounding volume that 933 Cre-GFP molecules is
VCreGFPtb = 9:333 10
2 3 387= 3:63 105 ðnmÞ3 (Equation 7)
which is about 40.7% of the volume of bounding hollow sphere for Cre-GFP proteins (VCreGFPhs ) and 12.9% of all the intra-Gectosome
space volume (Vti ).
3D Space-Filling of VSV-G-GFP11 and Cre-GFP1-10 Molecules in a Gectosome
We used an open-source 3D software Blender (https://www.blender.org) and the ePMV add-on to model the complemented VSV-G-
GFP11 and Cre-GFP1-10 molecules in a Gectosome. The model is based on the space-filling model of the corresponding PDB pro-
tein structures at the nanometer scale. The protein structure of VSV-G, GFP11, and Cre-GFP1-10 monomers were represented with
"Coarse Molecular Surface" by importing corresponding PDB structure file to ePMV in Blender. The unknown linker domains (e.g.:
transmembrane domain) of the fused proteins were simplified as a cylinder, which links the VSV-G in the extra-Gectosome and the
complemented sfGFP/Cre proteins. The outside view and the middle intersection view of the 3D model are illustrated in Figure 3F.
Estimation of the Partial Specific Volume for Proteins Identified from Mass Spectrometry Data
To quantify the relative abundance of the proteins found in the Gectosome, we used the label-free quantitation (LFQ) method based
on the mass spectrometry data (Cox et al., 2014). The relative molar abundance of a protein was calculated by normalizing their LFQ
values to the LFQ value for VSV-G protein. Based on the measured absolute abundance of VSV-G protein in Gectosome (5.623103


















To calculate the intra-Gectosome and extra-Gectosome protein volumes, we first identified the vesicle membrane proteins in the
MS data using online software DAVID Bioinformatics Resources 6.8 (https://david.ncifcrf.gov/). The predicted partial specific vol-
umes of the proteins in a Gectosome are listed in Table S2.
QUANTIFICATION AND STATISTICAL ANALYSIS
Image Analysis
The size of Gectosomes from TEM imagewasmeasured by using SerialEM software on transmission electronmicroscopy. The quan-
titative analysis of the colocalization of complemented split GFP (VSV-G-GFP11/Cre-GFP1-10) and EEA1(n=37) or Lamp1(n=47) in
HeLa cells were performed using the Jacop Plugin of ImageJ and the data are expressed as a Pearson’s coefficient (r).
Statistical Analysis
Statistical analyses of data were performed with GraphPad Prism 7. Data are represented as mean ± standard deviation or mean ±
SEM or average ± standard error as indicated. For comparisons between two groups, statistical significance was determined using
an unpaired student’s t-test. The two-way ANOVAwas used to compare the effects of different groups of treatments on PCSK9, LDL-
cholesterol, and body weight of animals. Parkin localization on mitochondria was assessed with the MetaXpress application module
called Transfluor Cell Scoring Application Module (Molecular Devices). Flow cytometric analysis was typically performed in three
technical replicates (n=3) and the number of biological replicates is indicated for specific experiment in figure legends. Specific sam-
ple sizes, including the number of particles, cells, mice in each experiment, and p-values are indicated in figures and figure legends.
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